<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="nihpa"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC4387236/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Genome-wide Association Study of Virologic Response with Efavirenz- or Abacavir-containing Regimens in AIDS Clinical Trials Group Protocols</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css"><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387236/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Pharmacogenetics and genomics"><meta name="citation_title" content="Genome-wide Association Study of Virologic Response with Efavirenz- or Abacavir-containing Regimens in AIDS Clinical Trials Group Protocols"><meta name="citation_authors" content="David S. Lehmann, Heather J. Ribaudo, Eric S. Daar, Roy M. Gulick, Richard H. Haubrich, Gregory K. Robbins, Paul I.W. de Bakker, David W. Haas, Paul J. McLaren"><meta name="citation_date" content="February 2015"><meta name="citation_issue" content="2"><meta name="citation_volume" content="25"><meta name="citation_firstpage" content="51"><meta name="citation_doi" content="10.1097/FPC.0000000000000106"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC4387236/?report=abstract"><meta name="citation_pmid" content="25461247"><meta name="DC.Title" content="Genome-wide Association Study of Virologic Response with Efavirenz- or Abacavir-containing Regimens in AIDS Clinical Trials Group Protocols"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="NIH Public Access"><meta name="DC.Contributor" content="David S. Lehmann"><meta name="DC.Contributor" content="Heather J. Ribaudo"><meta name="DC.Contributor" content="Eric S. Daar"><meta name="DC.Contributor" content="Roy M. Gulick"><meta name="DC.Contributor" content="Richard H. Haubrich"><meta name="DC.Contributor" content="Gregory K. Robbins"><meta name="DC.Contributor" content="Paul I.W. de Bakker"><meta name="DC.Contributor" content="David W. Haas"><meta name="DC.Contributor" content="Paul J. McLaren"><meta name="DC.Date" content="2015 Feb"><meta name="DC.Identifier" content="10.1097/FPC.0000000000000106"><meta name="DC.Language" content="en"><meta property="og:title" content="Genome-wide Association Study of Virologic Response with Efavirenz- or Abacavir-containing Regimens in AIDS Clinical Trials Group Protocols"><meta property="og:type" content="article"><meta property="og:description" content="Efavirenz and abacavir are components of recommended first-line regimens for human immunodeficiency virus (HIV)-1 infection. We used genome-wide genotyping and clinical data to explore genetic associations with virologic failure among subjects randomized ..."><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387236/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><meta name="ncbi_feature" content="associated_data"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'"><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css"><script type="text/javascript" src="/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-hhspa.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><meta name="cited_in_systematic_reviews" content=""><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC4387236/epub/"><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC4387236/pdf/nihms668995.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="CE8C28A4DD573F2100000000079E049F.m_8">
<meta name="referrer" content="origin-when-cross-origin"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print"><script async="1" src="https://www.google-analytics.com/analytics.js"></script><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1px; bottom: 2px; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-ncbiexternallink-4"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi" style="top: -0.4em;"><iframe src="https://eutils.ncbi.nlm.nih.gov/entrez/eutils/emyncbi.fcgi?cmd=htmlportal&amp;currenturl=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4387236%2F" style="border:none; height:2.5em; width:40em;" scrolling="no"></iframe></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="jig-ncbiclearbutton-wrap ui-ncbiclearbutton-wrap box-shadow"><input name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'yes'" aria-haspopup="true" aria-autocomplete="list" role="textbox" type="text"><a class="reset" href="#" style="visibility: hidden;"><img src="/core/jig/1.14.8/img/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a></li><li class="accid">PMC4387236</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-hhspa.png" alt="Logo of nihpa" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,57,255,75" alt="About Author manuscripts" title="About Author manuscripts" href="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html" ref="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html"><area shape="rect" coords="256,57,500,75" alt="Submit a manuscript" title="Submit a manuscript" href="https://www.nihms.nih.gov/" ref="reftype=publisher&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="0,0,499,74" alt="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" title="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" href="https://www.ncbi.nlm.nih.gov/pmc/about/public-access/" ref="reftype=publisher&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" id="ui-ncbiinpagenav-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><span role="menubar"><a href="#" role="menuitem" aria-expanded="false" aria-haspopup="true">Pharmacogenet Genomics</a></span>. Author manuscript; available in PMC 2015 Apr 7.</div><div></div><div>Published in final edited form as:</div><div style="margin-left:1em"><div class="fm-vol-iss-date"><a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=25461247" target="pmc_ext" ref="reftype=publisher&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access"><span class="cit">Pharmacogenet Genomics. 2015 Feb; 25(2): 51–59. </span></a></div> <span class="doi">doi:&nbsp;<a href="//dx.doi.org/10.1097%2FFPC.0000000000000106" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1097/FPC.0000000000000106</a></span></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC4387236</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">NIHMSID: </span><span>NIHMS668995</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/25461247">25461247</a></div></div></div></div><h1 class="content-title">Genome-wide Association Study of Virologic Response with Efavirenz- or Abacavir-containing Regimens in AIDS Clinical Trials Group Protocols</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Lehmann%20DS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247" class="affpopup" co-rid="_co_idm140660880149824" co-class="co-affbox">David S. Lehmann</a>,<sup>1</sup> <a href="/pubmed/?term=Ribaudo%20HJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247" class="affpopup" co-rid="_co_idm140660877899312" co-class="co-affbox">Heather J. Ribaudo</a>, PhD,<sup>2</sup> <a href="/pubmed/?term=Daar%20ES%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247" class="affpopup" co-rid="_co_idm140660839729376" co-class="co-affbox">Eric S. Daar</a>, MD,<sup>3</sup> <a href="/pubmed/?term=Gulick%20RM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247" class="affpopup" co-rid="_co_idm140660841093968" co-class="co-affbox">Roy M. Gulick</a>, MD,<sup>4</sup> <a href="/pubmed/?term=Haubrich%20RH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247" class="affpopup" co-rid="_co_idm140660842056272" co-class="co-affbox">Richard H. Haubrich</a>, MD,<sup>5</sup> <a href="/pubmed/?term=Robbins%20GK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247" class="affpopup" co-rid="_co_idm140660880063056" co-class="co-affbox">Gregory K. Robbins</a>, MD,<sup>6</sup> <a href="/pubmed/?term=de%20Bakker%20PI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247" class="affpopup" co-rid="_co_idm140660843571008" co-class="co-affbox">Paul I.W. de Bakker</a>, PhD,<sup>7</sup> <a href="/pubmed/?term=Haas%20DW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247" class="affpopup" co-rid="_co_idm140660877495392" co-class="co-affbox">David W. Haas</a>, MD,<sup>8</sup> and  <a href="/pubmed/?term=McLaren%20PJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247" class="affpopup" co-rid="_co_idm140660838407504" co-class="co-affbox">Paul J. McLaren</a>, PhD<sup>9,</sup><sup>10</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140660880149824"><h3 class="no_margin">David S. Lehmann</h3><p><sup>1</sup>Brandeis University, Waltham, Massachusetts, USA</p><div>Find articles by <a href="/pubmed/?term=Lehmann%20DS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247">David S. Lehmann</a></div></div><div id="_co_idm140660877899312"><h3 class="no_margin">Heather J. Ribaudo</h3><p><sup>2</sup>Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA</p><div>Find articles by <a href="/pubmed/?term=Ribaudo%20HJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247">Heather J. Ribaudo</a></div></div><div id="_co_idm140660839729376"><h3 class="no_margin">Eric S. Daar</h3><p><sup>3</sup>Los Angeles Biomed Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA</p><div>Find articles by <a href="/pubmed/?term=Daar%20ES%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247">Eric S. Daar</a></div></div><div id="_co_idm140660841093968"><h3 class="no_margin">Roy M. Gulick</h3><p><sup>4</sup>Weill Cornell Medical College, New York, NY, United States</p><div>Find articles by <a href="/pubmed/?term=Gulick%20RM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247">Roy M. Gulick</a></div></div><div id="_co_idm140660842056272"><h3 class="no_margin">Richard H. Haubrich</h3><p><sup>5</sup>University of California San Diego, San Diego, California, USA</p><div>Find articles by <a href="/pubmed/?term=Haubrich%20RH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247">Richard H. Haubrich</a></div></div><div id="_co_idm140660880063056"><h3 class="no_margin">Gregory K. Robbins</h3><p><sup>6</sup>Harvard Medical School, Boston, Massachusetts, USA</p><div>Find articles by <a href="/pubmed/?term=Robbins%20GK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247">Gregory K. Robbins</a></div></div><div id="_co_idm140660843571008"><h3 class="no_margin">Paul I.W. de Bakker</h3><p><sup>7</sup>Departments of Medical Genetics and of Epidemiology, University Medical Center Utrecht, Utrecht, The Netherlands</p><div>Find articles by <a href="/pubmed/?term=de%20Bakker%20PI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247">Paul I.W. de Bakker</a></div></div><div id="_co_idm140660877495392"><h3 class="no_margin">David W. Haas</h3><p><sup>8</sup>Vanderbilt University School of Medicine, Nashville, Tennessee, USA</p><div>Find articles by <a href="/pubmed/?term=Haas%20DW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247">David W. Haas</a></div></div><div id="_co_idm140660838407504"><h3 class="no_margin">Paul J. McLaren</h3><p><sup>9</sup>School of Life Sciences, The Swiss Institute of Technology, Lausanne, Switzerland</p><p><sup>10</sup>Institute of Microbiology University Hospital, University of Lausanne, Lausanne, Switzerland</p><div>Find articles by <a href="/pubmed/?term=McLaren%20PJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25461247">Paul J. McLaren</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140660824403952_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140660824403952_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140660824403952_ai" style="display:none"><div class="fm-affl" id="A1" lang="en"><sup>1</sup>Brandeis University, Waltham, Massachusetts, USA</div><div class="fm-affl" id="A2" lang="en"><sup>2</sup>Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA</div><div class="fm-affl" id="A3" lang="en"><sup>3</sup>Los Angeles Biomed Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA</div><div class="fm-affl" id="A4" lang="en"><sup>4</sup>Weill Cornell Medical College, New York, NY, United States</div><div class="fm-affl" id="A5" lang="en"><sup>5</sup>University of California San Diego, San Diego, California, USA</div><div class="fm-affl" id="A6" lang="en"><sup>6</sup>Harvard Medical School, Boston, Massachusetts, USA</div><div class="fm-affl" id="A7" lang="en"><sup>7</sup>Departments of Medical Genetics and of Epidemiology, University Medical Center Utrecht, Utrecht, The Netherlands</div><div class="fm-affl" id="A8" lang="en"><sup>8</sup>Vanderbilt University School of Medicine, Nashville, Tennessee, USA</div><div class="fm-affl" id="A9" lang="en"><sup>9</sup>School of Life Sciences, The Swiss Institute of Technology, Lausanne, Switzerland</div><div class="fm-affl" id="A10" lang="en"><sup>10</sup>Institute of Microbiology University Hospital, University of Lausanne, Lausanne, Switzerland</div><div id="cor1"><strong>Corresponding author information:</strong> Paul J McLaren, PhD, Junior Group Leader in Bioinformatics, EPFL SV-GHI-GR-FE, Station 19, CH-1015 Lausanne, Switzerland, Phone: +41 (0) 21 693 18 74, FAX: +41 (0) 21 693 72 20, <a href="mailto:dev@null" data-email="hc.lfpe@neralcm.luap" class="oemail">hc.lfpe@neralcm.luap</a></div></div><div class="fm-article-notes fm-panel half_rhythm"></div><div class="permissions fm-panel half_rhythm hide" id="idm140660824403952_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright notice</a> </div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>The publisher's final edited version of this article is available  at <a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=25461247" target="pmc_ext" ref="reftype=publisher&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access">Pharmacogenet Genomics</a></div><div>See other articles in PMC that <a href="/pmc/articles/PMC4387236/citedby/">cite</a> the published article.</div></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><div class="goto jig-ncbiinpagenav-goto-container"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true">Go to:</a></span></div><h2 class="ui-helper-clearfix" id="ui-ncbiinpagenav-heading-3">Associated Data</h2><dl data-count="2" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>1.</strong></div><div><a href="/pmc/articles/PMC4387236/bin/NIHMS668995-supplement-1.doc" data-ga-action="click_feat_suppl">NIHMS668995-supplement-1.doc</a><span style="color:gray"> (124K)</span></div><div class="small guid">GUID:&nbsp;F4E7FBA9-0B08-41D3-A6CE-475812656D4E</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>2.</strong></div><div><a href="/pmc/articles/PMC4387236/bin/NIHMS668995-supplement-2.doc" data-ga-action="click_feat_suppl">NIHMS668995-supplement-2.doc</a><span style="color:gray"> (123K)</span></div><div class="small guid">GUID:&nbsp;5C8D0D46-D6B0-47C4-9D3E-7950DAA7D58E</div></div></dd></dl></div><div id="idm140660840931824" class="tsec sec" lang="en"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140660840931824title">Abstract</h2><!--article-meta--><div><div id="S1" class="sec sec-first"><h3 id="S1title">Background</h3><p id="P1" class="p p-first-last">Efavirenz and abacavir are components of recommended first-line regimens for human immunodeficiency virus (HIV)-1 infection. We used genome-wide genotyping and clinical data to explore genetic associations with virologic failure among subjects randomized to efavirenz- or abacavir-containing regimens in AIDS Clinical Trials Group (ACTG) protocols.</p></div><div id="S2" class="sec"><h3 id="S2title">Methods</h3><p id="P2" class="p p-first-last">Virologic response and genome-wide genotype data were available from treatment-naive subjects randomized to efavirenz-containing (n=1,596) or abacavir-containing (n=786) regimens in ACTG protocols 384, A5142, A5095, and A5202.</p></div><div id="S3" class="sec"><h3 id="S3title">Results</h3><p id="P3" class="p p-first-last">Meta-analysis of association results across race/ethnic groups showed no genome-wide significant associations (p&lt;5×10<sup>−8</sup>) with virologic response for either efavirenz or abacavir. Our sample size provided 80% power to detect a genotype relative risk of 1.8 for efavirenz, and 2.4 for abacavir. Analyses focused on <em>CYP2B</em> genotypes that define the lowest plasma efavirenz exposure stratum did not reveal associations, nor did analysis limited to gene sets predicted to be relevant to efavirenz and abacavir disposition.</p></div><div id="S4" class="sec sec-last"><h3 id="S4title">Conclusions</h3><p id="P4" class="p p-first-last">No single polymorphism is strongly associated with virologic failure with efavirenz- or abacavir-containing regimens. Analyses to better consider context, and that minimize confounding by non-genetic factors, may reveal associations not apparent herein.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">HIV-1, efavirenz, abacavir, pharmacogenomics, virologic failure</span></div></div><div id="S5" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S5title">Introduction</h2><p id="P5" class="p p-first">The non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz, and the nucleoside reverse transcriptase inhibitor (NRTI) abacavir are components of recommended first-line regimens for human immunodeficiency virus (HIV)-1 infection [<a href="#R1" rid="R1" class=" bibr popnode">1</a>]. Approximately 15–20% of individuals randomized to efavirenz-containing regimens in prospective clinical trials met virologic failure endpoints at week 48 [<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370831">2</a>–<a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370812">9</a>]. Limited data from candidate gene studies suggest that genetic polymorphisms may affect virologic response. An initial report identified an association between an <em>ABCB1</em> polymorphism (which encodes P-glycoprotein) and virologic response to efavirenz-containing regimens in the Swiss HIV Cohort Study [<a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370820">10</a>]. A subsequent analysis involving two AIDS Clinical Trials Group (ACTG) protocols suggested increased virologic failure of efavirenz-containing regimens associated with <em>CYP2B6</em> polymorphisms in African Americans, but not in whites or Hispanics [<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370808">11</a>]. This gene encodes cytochrome P450 (CYP) 2B6, the primary metabolic pathway for efavirenz [<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370794">12</a>]. In contrast, a recent analysis of data from prospective randomized clinical trial HT 001 in Port au Prince, Haiti found no association between <em>CYP2B6</em> polymorphisms and likelihood of virologic failure [<a href="#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370852">13</a>].</p><p id="P6">Increased plasma efavirenz exposure is associated with several <em>CYP2B6</em> loss-of-function polymorphisms, 516G→T (rs3745274) [<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370834">14</a>–<a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370838">19</a>], 983T→C (rs28399499) [<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370823">11</a>, <a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370819">19</a>–<a href="#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370853">21</a>], and 15582C→T (rs4803419) [<a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370801">19</a>]. The greater frequency of <em>CYP2B6</em> 516G→T in individuals of African ancestry compared to European ancestry [<a href="#R22" rid="R22" class=" bibr popnode">22</a>] largely explains the greater mean plasma efavirenz concentrations in the former group [<a href="#R23" rid="R23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370814">23</a>, <a href="#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370815">24</a>]. <em>CYP2B6</em> 983T→C is also more frequent in Africans, although far less frequent overall than 516G→T, and is virtually absent from populations of European ancestry [<a href="#R22" rid="R22" class=" bibr popnode">22</a>]. <em>CYP2B6</em> 15582C→T is more frequent with European or Asian ancestry than with African ancestry [<a href="#R22" rid="R22" class=" bibr popnode">22</a>], and its effect on efavirenz concentrations is modest compared to those of <em>CYP2B6</em> 516G→T and 983T→C [<a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370848">19</a>]. The three <em>CYP2B6</em> polymorphisms reside on mutually exclusive haplotypes, and various two-way combinations of these polymorphisms define plasma efavirenz exposure strata that span an approximately 10-fold range [<a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370828">19</a>].</p><p id="P7">All recommended initial regimens for HIV-1 infection include either abacavir/lamivudine or tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), each in combination with a third drug from a different class (an NNRTI, a protease inhibitor with low-dose ritonavir as a pharmacokinetic enhancer, or an integrase inhibitor) [<a href="#R1" rid="R1" class=" bibr popnode">1</a>]. Abacavir is metabolized primarily by alcohol dehydrogenase and glucuronyl transferase, with minimal metabolism by CYP enzymes. Its active 5-triphosphate metabolite, carbovir triphosphate, is generated intracellularly [<a href="#R25" rid="R25" class=" bibr popnode">25</a>]. While carriage of <em>HLA-B*57:01</em> is a strong predictor of hypersensitivity reactions to abacavir [<a href="#R26" rid="R26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370784">26</a>–<a href="#R28" rid="R28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370789">28</a>], genetic predictors of other responses or pharmacokinetic parameters with abacavir have not been reported.</p><p id="P8">Randomized clinical trials have assessed the safety and efficacy of abacavir in combination with other drugs. Study A5202 compared abacavir/lamivudine with TDF/ FTC, each in combination with either efavirenz or atazanavir/ritonavir. In A5202, among subjects with pre-treatment plasma HIV-1 RNA ≥100,000 copies/mL, virologic response was inferior with abacavir/lamivudine versus TDF/emtricitabine, but responses were equivalent with lower pre-treatment plasma HIV-1 RNA concentrations [<a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370792">29</a>]. A study of NRTIs in combination with lopinavir/ritonavir found no difference in virologic response between abacavir/lamivudine and TDF/FTC [<a href="#R30" rid="R30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370780">30</a>]. In the SINGLE trial, which compared abacavir/lamivudine + dolutegravir with TDF/FTC/efavirenz, virologic responses between abacavir/lamivudine and TDF/FTC did not differ in patients with high pre-treatment plasma HIV-1 RNA concentrations [<a href="#R31" rid="R31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370813">31</a>]. Thus, differences in responses with ABC-containing regimens could be due to the third drug, but current data does not exclude potential pharmacogenomics effects on outcome.</p><p id="P9" class="p p-last">In the present study we used a genome-wide approach to evaluate whether common human genetic variants were associated with virologic failure among treatment-naïve subjects who initiated efavirenz- or abacavir-containing regimens in prospective, randomized ACTG clinical trials.</p></div><div id="S6" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S6title">Methods</h2><div id="S7" class="sec sec-first"><h3 id="S7title">Study Participants</h3><p id="P10" class="p p-first-last">Treatment-naïve subjects were randomized to efavirenz-containing regimens in ACTG studies 384 [<a href="#R32" rid="R32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_530566704">32</a>, <a href="#R33" rid="R33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_530566706">33</a>], A5095 [<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370781">2</a>], A5142 [<a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370790">4</a>], and A5202 [<a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370829">7</a>, <a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370824">29</a>], and to abacavir-containing regimens in A5095 [<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370826">2</a>] and A5202 [<a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370816">7</a>, <a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370795">29</a>], with DNA obtained under protocol A5128 [<a href="#R34" rid="R34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370785">34</a>]. Some subjects from ACTG 384 and A5095 were also included in previous candidate gene analyses of virologic response to efavirenz-containing regimens [<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370804">11</a>]. For efavirenz, concomitant antiretrovirals included once-daily TDF/FTC [<a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370786">7</a>, <a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370844">29</a>]; once-daily abacavir/lamivudine [<a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370851">7</a>, <a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370850">29</a>]; twice-daily zidovudine/lamivudine [<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370849">2</a>, <a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370822">4</a>, <a href="#R32" rid="R32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_530566702">32</a>, <a href="#R33" rid="R33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_530566705">33</a>], twice-daily zidovudine/lamivudine/abacavir [<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370830">2</a>], once daily stavudine (d4T)/lamivudine [<a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370841">4</a>, <a href="#R32" rid="R32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_530566703">32</a>, <a href="#R33" rid="R33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_530566701">33</a>]; once-daily TDF/ lamivudine [<a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370835">4</a>]; and twice-daily lopinavir/ritonavir [<a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370783">4</a>]. For abacavir, concomitant antiretrovirals included once-daily efavirenz/lamivudine [<a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370845">7</a>, <a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370797">29</a>]; once-daily atazanavir/ritonavir/lamivudine [<a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370811">7</a>, <a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370846">29</a>]; once daily efavirenz with twice-daily zidovudine/lamivudine [<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370782">2</a>]; and twice-daily zidovudine/lamivudine [<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370788">2</a>]. Abacavir was prescribed once daily in A5202, and twice daily in A5095. Self-identified race/ethnicity categories "white, non-Hispanic", "black, non-Hispanic", and "Hispanic" are hereafter referred to as white, black, and Hispanic, respectively. This study complied with the Helsinki Declaration, was approved by institutional review boards for each site, and subjects gave written informed consent.</p></div><div id="S8" class="sec"><h3 id="S8title">Definitions of virologic response</h3><p id="P11" class="p p-first-last">Three complementary definitions for virologic response were used for case/control analyses. These included 1) HIV-1 RNA &lt;50 copies/mL at ≤16 weeks, 2) HIV-1 RNA &gt;200 copies/mL after HIV-1 RNA &lt;200 copies/mL and 3) virologic response at week 48 (HIV-1 RNA &lt;50 copies/mL at 48 weeks). The week 48 virology response definition was based on a single, cross-sectional plasma HIV-1 RNA determination. The other two virology response definitions required confirmation by a second HIV-1 RNA determination at a separate study visit. The first two of these endpoints were defined to reflect 1) rapidity and 2) maintenance of virologic response while accommodating the differing visit schedules across the studies. The third endpoint was defined for its clinical relevance in the setting of treatment for HIV-1. To limit confounding of non-virologic factors, analyses of the first endpoint were limited to individuals who remained on the drug of interest for at least 8 weeks, analyses of the second endpoint were limited to individuals who achieved HIV-1 RNA&lt;200 copies/ml while on initial treatment, and analyses of the third endpoint were limited to individuals who remained on randomized treatment for 48 weeks. To address possible confounding by differential adherence, sub-analyses including only patients with no reported missing doses were also carried out.</p></div><div id="S9" class="sec"><h3 id="S9title">Genotyping</h3><p id="P12" class="p p-first-last">The Vanderbilt Institutional Review Boards and the ACTG approved this use of DNA. Genome-wide polymorphism data was obtained as part of the International HIV Controllers study as described [<a href="#R35" rid="R35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370803">35</a>]. Briefly, samples were genotyped on either the Illumina HumanHap 650Y or 1M-Duo platform. Data quality control included removal of population outliers, highly related individuals and individuals with highly missing genotype data. Polymorphisms were excluded for low frequency (&lt;1%), high missingness (&gt;5%) or deviation from Hardy-Weinberg expectation (Fisher’s exact test p&lt;5e-6) using PLINK version 1.07 [<a href="#R36" rid="R36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370847">36</a>]. Genetic ancestry was determined using principal components analysis in EIGENSTRAT [<a href="#R37" rid="R37" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370821">37</a>]. Based on comparison with HapMap phase 3 populations, data were clustered into Black, White and Hispanic groups for analysis. After quality control, unobserved genotypes were imputed using the 1,000 Genomes Project Phase I release integrated polymorphisms and indels (March 2012) and BEAGLE software version 4 [<a href="#R38" rid="R38" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370802">38</a>]. After imputation, &gt;8 million high-quality polymorphisms were tested for association.</p></div><div id="S10" class="sec"><h3 id="S10title">Association testing</h3><p id="P13" class="p p-first">Per ethnic group and per response phenotype, association was tested at each polymorphism using logistic regression including top principal components as covariates to correct for residual population structure. To control for the impact of concomitant medication on association signals we included categorical covariates depending on the full ART regimen per patient. For EFV-containing regimens we defined four groups: 1) TDF/FTC/EFV containing regimens 2) once-daily ABC/3TC/EFV regimens 3) PI-containing regimens 4) twice-daily ZDV or d4T containing regimens without PIs. For ABC-containing regimens, we defined two groups: 1) ABC/3TC/EFV-containing regimens 2) ABC/3TC/ZDV regimens. Additionally, we included pre-treatment CD4+ T cell count and viral load as covariates to account for their potential influence on virologic response. This was sufficient to correct for inflation in all cases (genomic inflation factor ~1, <a href="/pmc/articles/PMC4387236/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>,<a href="/pmc/articles/PMC4387236/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -0.5em;">,2).</span></span><span>2</span></a>). Data were combined across ethnic groups using inverse-variance weighted meta-analysis. Association results for all variants tested in each analysis are available upon request.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC4387236/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140660833095376" class="figure"><a href="/pmc/articles/PMC4387236/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4387236_nihms668995f1.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms668995f1.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC4387236/bin/nihms668995f1.jpg"></a></div><div id="largeobj_idm140660833095376" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC4387236/figure/F1/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC4387236/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Associations between genetic polymorphisms and virologic response phenotypes in subjects randomized to efavirenz-containing regimens</strong><p id="P42">Results visualized by QQ plots (left panels) and Manhattan plots (right panels) represent meta-analysis involving all three ethnic groups. Association results for each group, calculated by logistic regression, were meta-analyzed using inverse-variance weighting for the phenotypes: (A) plasma HIV-1 RNA &lt;50 copies/mL at ≤16 weeks; (B) HIV-1 RNA &gt;200 copies/mL after being &lt;200 copies/mL; (C) HIV-1 RNA &lt;50 copies/mL at 48 weeks. On each QQ plot the dashed line indicates the null expectation. On each Manhattan plot the dashed line indicates the threshold of genome-wide significance (p&lt;5×10<sup>−8</sup>).</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC4387236/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140660825958496" class="figure"><a href="/pmc/articles/PMC4387236/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4387236_nihms668995f2.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms668995f2.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC4387236/bin/nihms668995f2.jpg"></a></div><div id="largeobj_idm140660825958496" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC4387236/figure/F2/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC4387236/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Associations between genetic polymorphisms and virologic response phenotypes in subjects randomized to abacavir-containing regimens</strong><p id="P43">Results visualized by QQ plots (left panels) and Manhattan plots (right panels) represent meta-analysis involving all three ethnic groups. Association results for each ethnic group calculated by logistic regression were meta-analyzed using inverse-variance weighting for the phenotypes: (A) plasma HIV-1 RNA &lt;50 copies/mL at ≤16 weeks; (B) HIV-1 RNA &gt;200 copies/mL after being &lt;200 copies/mL; (C) HIV-1 RNA &lt;50 copies/mL at 48 weeks. On each QQ plot the dashed line indicates the null expectation. On each Manhattan plot the dashed line indicates the threshold of genome-wide significance (p&lt;5×10<sup>−8</sup>).</p></div></div></div><p id="P14" class="p p-last">Power for variant detection was calculated post-hoc using the online genetic power calculator [<a href="#R39" rid="R39" class=" bibr popnode">39</a>] and assumed a 10% causal allele frequency, a trait prevalence of 0.1, the observed sample size and genome-wide significance level for detection of association (p&lt;5×10<sup>−8</sup>).</p></div><div id="S11" class="sec"><h3 id="S11title">Targeted analysis of <em>CYP2B6</em> haplotypes</h3><p id="P15" class="p p-first-last">Since combinations of alleles at rs3745274, rs28399499, and rs4803419 are known to influence plasma EFV exposure we directly tested these SNPs in a targeted analysis. We built haplotypes spanning these SNPs, testing individuals homozygous for the CC/GG/CC haplotype (known to result in the lowest stratum of plasma EFV levels) against all others using the same testing framework and covariates as the genome-wide analysis.</p></div><div id="S12" class="sec sec-last"><h3 id="S12title">Gene set enrichment testing</h3><p id="P16" class="p p-first-last">To assess for enrichment of association signal across pathways we used MAGENTA [<a href="#R40" rid="R40" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370817">40</a>]. A custom gene set of 240 ADME genes was compiled (list of genes in Supplemental Material). Based on a survey of the literature, we broadly included ADME genes of potential relevance to efavirenz or abacavir, and excluded ADME genes almost certain to not be relevant to each drug. Ninety-eight of these genes were implicated in abacavir metabolism, and 145 in efavirenz metabolism (of which 7 were considered strongly influential, <a href="#SD2" rid="SD2" class=" supplementary-material">Table S1</a>). In addition we tested sets of pre-defined pathways from sources including Gene Ontology (GO) terms, PANTHER (biological processes, molecular functions, metabolic and signaling pathways), KEGG, and Ingenuity. We used an FDR cutoff of 95% to consider pathways or custom gene sets as significantly associated.</p></div></div><div id="S13" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S13title">Results</h2><div id="S14" class="sec sec-first"><h3 id="S14title">Genetic associations with virologic failure</h3><p id="P17" class="p p-first">A total of 1,596 subjects randomized to efavirenz-containing regimens, and 786 subjects randomized to abacavir-containing regimens had sufficient clinical and genome-wide polymorphism data for analysis in the three phenotypic strata (<a href="/pmc/articles/PMC4387236/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). After genotype imputation, we tested &gt;8 million polymorphisms for association with the three virologic response categories in all ethnic groups by logistic regression, including covariates to account for genetic population structure, concomitant medications and pre-treatment clinical markers (see methods). Evidence was combined across ethnic groups by meta-analysis.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p id="P44">Sample numbers and power estimates in each analysis stratified by antiretroviral, phenotype, and race/ethnicity group.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140660833229776" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="top" align="left">Group</th><th rowspan="1" colspan="1" valign="top" align="left">Phenotype</th><th rowspan="1" colspan="1" valign="top" align="center">Cases</th><th rowspan="1" colspan="1" valign="top" align="center">Controls</th><th rowspan="1" colspan="1" valign="top" align="center">Total</th><th rowspan="1" colspan="1" align="center">GRR<sup>a</sup> for<br>80% Power</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" align="left"><em>Efavirenz</em></td><td rowspan="1" colspan="1" align="left"></td><td rowspan="1" colspan="1" align="center"></td><td rowspan="1" colspan="1" align="center"></td><td rowspan="1" colspan="1" align="center"></td><td rowspan="1" colspan="1" align="center"></td></tr><tr><td rowspan="1" colspan="1" align="left">&nbsp;&nbsp;White</td><td rowspan="1" colspan="1" align="left">Suppression at 16 weeks</td><td rowspan="1" colspan="1" align="center">343</td><td rowspan="1" colspan="1" align="center">169</td><td rowspan="1" colspan="1" align="center">512</td><td rowspan="1" colspan="1" align="center">2.9</td></tr><tr><td rowspan="1" colspan="1" align="left"></td><td rowspan="1" colspan="1" align="left">Rebound</td><td rowspan="1" colspan="1" align="center">134</td><td rowspan="1" colspan="1" align="center">324</td><td rowspan="1" colspan="1" align="center">458</td><td rowspan="1" colspan="1" align="center">3.1</td></tr><tr><td rowspan="1" colspan="1" align="left"></td><td rowspan="1" colspan="1" align="left">Suppression at 48 weeks</td><td rowspan="1" colspan="1" align="center">365</td><td rowspan="1" colspan="1" align="center">372</td><td rowspan="1" colspan="1" align="center">737</td><td rowspan="1" colspan="1" align="center">2.4</td></tr><tr><td rowspan="1" colspan="1" align="left">&nbsp;&nbsp;Black</td><td rowspan="1" colspan="1" align="left">Suppression at 16 weeks</td><td rowspan="1" colspan="1" align="center">301</td><td rowspan="1" colspan="1" align="center">115</td><td rowspan="1" colspan="1" align="center">416</td><td rowspan="1" colspan="1" align="center">3.3</td></tr><tr><td rowspan="1" colspan="1" align="left"></td><td rowspan="1" colspan="1" align="left">Rebound</td><td rowspan="1" colspan="1" align="center">158</td><td rowspan="1" colspan="1" align="center">207</td><td rowspan="1" colspan="1" align="center">365</td><td rowspan="1" colspan="1" align="center">3.5</td></tr><tr><td rowspan="1" colspan="1" align="left"></td><td rowspan="1" colspan="1" align="left">Suppression at 48 weeks</td><td rowspan="1" colspan="1" align="center">252</td><td rowspan="1" colspan="1" align="center">293</td><td rowspan="1" colspan="1" align="center">545</td><td rowspan="1" colspan="1" align="center">2.8</td></tr><tr><td rowspan="1" colspan="1" align="left">&nbsp;&nbsp;Hispanic</td><td rowspan="1" colspan="1" align="left">Suppression at 16 weeks</td><td rowspan="1" colspan="1" align="center">139</td><td rowspan="1" colspan="1" align="center">57</td><td rowspan="1" colspan="1" align="center">196</td><td rowspan="1" colspan="1" align="center">5.8</td></tr><tr><td rowspan="1" colspan="1" align="left"></td><td rowspan="1" colspan="1" align="left">Rebound</td><td rowspan="1" colspan="1" align="center">58</td><td rowspan="1" colspan="1" align="center">122</td><td rowspan="1" colspan="1" align="center">180</td><td rowspan="1" colspan="1" align="center">6.2</td></tr><tr><td rowspan="1" colspan="1" align="left"></td><td rowspan="1" colspan="1" align="left">Suppression at 48 weeks</td><td rowspan="1" colspan="1" align="center">137</td><td rowspan="1" colspan="1" align="center">177</td><td rowspan="1" colspan="1" align="center">314</td><td rowspan="1" colspan="1" align="center">3.9</td></tr><tr><td rowspan="3" colspan="1" valign="top" align="left">&nbsp;&nbsp;Meta-analysis of combined groups</td><td rowspan="1" colspan="1" valign="top" align="left">Suppression at 16 weeks</td><td rowspan="1" colspan="1" valign="top" align="center">783</td><td rowspan="1" colspan="1" valign="top" align="center">341</td><td rowspan="1" colspan="1" valign="top" align="center">1124</td><td rowspan="1" colspan="1" valign="top" align="center">2.1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Rebound</td><td rowspan="1" colspan="1" valign="top" align="center">350</td><td rowspan="1" colspan="1" valign="top" align="center">653</td><td rowspan="1" colspan="1" valign="top" align="center">1003</td><td rowspan="1" colspan="1" valign="top" align="center">2.1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Suppression at 48 weeks</td><td rowspan="1" colspan="1" valign="top" align="center">754</td><td rowspan="1" colspan="1" valign="top" align="center">842</td><td rowspan="1" colspan="1" valign="top" align="center">1596</td><td rowspan="1" colspan="1" valign="top" align="center">1.8</td></tr><tr><td rowspan="1" colspan="1" align="left"><em>Abacavir</em></td><td rowspan="1" colspan="1" align="left"></td><td rowspan="1" colspan="1" align="center"></td><td rowspan="1" colspan="1" align="center"></td><td rowspan="1" colspan="1" align="center"></td><td rowspan="1" colspan="1" align="center"></td></tr><tr><td rowspan="1" colspan="1" align="left">&nbsp;&nbsp;White</td><td rowspan="1" colspan="1" align="left">Suppression at 16 weeks</td><td rowspan="1" colspan="1" align="center">91</td><td rowspan="1" colspan="1" align="center">69</td><td rowspan="1" colspan="1" align="center">160</td><td rowspan="1" colspan="1" align="center">7.2</td></tr><tr><td rowspan="1" colspan="1" align="left"></td><td rowspan="1" colspan="1" align="left">Rebound</td><td rowspan="1" colspan="1" align="center">26</td><td rowspan="1" colspan="1" align="center">102</td><td rowspan="1" colspan="1" align="center">128</td><td rowspan="1" colspan="1" align="center">10.9</td></tr><tr><td rowspan="1" colspan="1" align="left"></td><td rowspan="1" colspan="1" align="left">Suppression at 48 weeks</td><td rowspan="1" colspan="1" align="center">106</td><td rowspan="1" colspan="1" align="center">240</td><td rowspan="1" colspan="1" align="center">346</td><td rowspan="1" colspan="1" align="center">3.7</td></tr><tr><td rowspan="1" colspan="1" align="left">&nbsp;&nbsp;Black</td><td rowspan="1" colspan="1" align="left">Suppression at 16 weeks</td><td rowspan="1" colspan="1" align="center">81</td><td rowspan="1" colspan="1" align="center">55</td><td rowspan="1" colspan="1" align="center">136</td><td rowspan="1" colspan="1" align="center">8.9</td></tr><tr><td rowspan="1" colspan="1" align="left"></td><td rowspan="1" colspan="1" align="left">Rebound</td><td rowspan="1" colspan="1" align="center">46</td><td rowspan="1" colspan="1" align="center">59</td><td rowspan="1" colspan="1" align="center">105</td><td rowspan="1" colspan="1" align="center">14.2</td></tr><tr><td rowspan="1" colspan="1" align="left"></td><td rowspan="1" colspan="1" align="left">Suppression at 48 weeks</td><td rowspan="1" colspan="1" align="center">68</td><td rowspan="1" colspan="1" align="center">197</td><td rowspan="1" colspan="1" align="center">265</td><td rowspan="1" colspan="1" align="center">4.6</td></tr><tr><td rowspan="1" colspan="1" align="left">&nbsp;&nbsp;Hispanic</td><td rowspan="1" colspan="1" align="left">Suppression at 16 weeks</td><td rowspan="1" colspan="1" align="center">46</td><td rowspan="1" colspan="1" align="center">32</td><td rowspan="1" colspan="1" align="center">78</td><td rowspan="1" colspan="1" align="center">na<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1" align="left"></td><td rowspan="1" colspan="1" align="left">Rebound</td><td rowspan="1" colspan="1" align="center">20</td><td rowspan="1" colspan="1" align="center">45</td><td rowspan="1" colspan="1" align="center">65</td><td rowspan="1" colspan="1" align="center">na<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1" align="left"></td><td rowspan="1" colspan="1" align="left">Suppression at 48 weeks</td><td rowspan="1" colspan="1" align="center">46</td><td rowspan="1" colspan="1" align="center">129</td><td rowspan="1" colspan="1" align="center">175</td><td rowspan="1" colspan="1" align="center">6.7</td></tr><tr><td rowspan="3" colspan="1" valign="top" align="left">&nbsp;&nbsp;Meta-analysis of combined groups</td><td rowspan="1" colspan="1" valign="top" align="left">Suppression at 16 weeks</td><td rowspan="1" colspan="1" valign="top" align="center">218</td><td rowspan="1" colspan="1" valign="top" align="center">156</td><td rowspan="1" colspan="1" valign="top" align="center">374</td><td rowspan="1" colspan="1" valign="top" align="center">3.4</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Rebound</td><td rowspan="1" colspan="1" valign="top" align="center">92</td><td rowspan="1" colspan="1" valign="top" align="center">206</td><td rowspan="1" colspan="1" valign="top" align="center">298</td><td rowspan="1" colspan="1" valign="top" align="center">4.1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Suppression at 48 weeks</td><td rowspan="1" colspan="1" valign="top" align="center">220</td><td rowspan="1" colspan="1" valign="top" align="center">566</td><td rowspan="1" colspan="1" valign="top" align="center">786</td><td rowspan="1" colspan="1" valign="top" align="center">2.4</td></tr></tbody></table></div><div id="largeobj_idm140660833229776" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC4387236/table/T1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN1"><sup>a</sup>GRR, genotype relative risk.</div><div id="TFN2"><sup>b</sup>na indicates the required GRR is out of range for the calculator</div></div></div><p id="P18">For efavirenz, we observed good behavior of the test statistic as visualized by QQ plots for each of the three virologic response definitions, indicating no residual inflation due to population structure (<a href="/pmc/articles/PMC4387236/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>). There were no genome-wide significant associations in any virologic response phenotype for efavirenz in any of the ethnic groups individually. Meta-analysis of association results across ethnic groups did not uncover any associations for efavirenz (<a href="/pmc/articles/PMC4387236/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>).</p><p id="P19">For abacavir, we also observed good behavior of the test statistic as visualized by QQ plots for each virologic response definition (<a href="/pmc/articles/PMC4387236/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2</span></a>). There were no genome-wide significant associations for any virologic response phenotype for abacavir. Meta-analysis of association results across ethnic groups did not uncover any associations for abacavir (<a href="/pmc/articles/PMC4387236/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2</span></a>). For both efavirenz and abacavir analyses, a list of SNPs with p-values below 1×10<sup>−5</sup> (top SNP per locus, pruned by linkage disequilibrium) is provided in Table S2.</p><p id="P20">To assess whether accounting for differential adherence may improve our ability to detect associations we restricted our analysis to subjects who were prescribed efavirenz or abacavir for at least 16 weeks (endpoint #1), or only subjects who reported no missed doses (endpoint #3). Neither sub-analysis revealed significant associations (data not shown).</p><p id="P21" class="p p-last">Given the available sample sizes, we calculated the genotypic relative risk required to provide ~80% power for detection. We were limited to detecting polymorphisms with very strong individual effects (<a href="/pmc/articles/PMC4387236/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). For efavirenz, the lowest genotype relative risk (GRR) that could be detected with ~80% power was HIV-1 RNA suppression at 48 weeks by meta-analysis across groups (detected GRR = 1.8). For abacavir, the lowest genotype relative risk (GRR) that could be detected with ~80% power was also HIV-1 RNA suppression at 48 weeks by meta-analysis across groups (detected GRR = 2.4).</p></div><div id="S15" class="sec"><h3 id="S15title">Genotypes that predict lower plasma efavirenz exposure do not impact virologic response</h3><p id="P22" class="p p-first-last">Pairwise combinations of three <em>CYP2B</em> polymorphisms (rs3745274, rs28399499, and rs4803419) are known to predict plasma efavirenz exposure [<a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370807">19</a>], with the lowest exposure stratum defined by homozygosity for the haplotype CC, GG, and CC, respectively, at these loci [<a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370818">19</a>]. We therefore tested whether carrying this haplotype was associated with increased risk for virologic failure. In analyses that compared this stratum to all other strata combined, there was no significant association with virologic failure (<a href="/pmc/articles/PMC4387236/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><p id="P47">Efavirenz virologic response comparison of lowest drug exposure genotype versus other genotypes.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140660830859536" class="xtable"><table frame="hsides" rules="none" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" align="left"></th><th colspan="2" rowspan="1" align="center">Suppression at 16 weeks</th><th colspan="2" rowspan="1" align="center">Rebound</th><th colspan="2" rowspan="1" align="center">Suppression at 48 weeks</th></tr><tr><th colspan="7" rowspan="1" valign="bottom" align="left"><hr></th></tr><tr><th rowspan="1" colspan="1" align="left"></th><th rowspan="1" colspan="1" align="center">OR<sup>1</sup></th><th rowspan="1" colspan="1" align="center">p-value</th><th rowspan="1" colspan="1" align="center">OR<sup>1</sup></th><th rowspan="1" colspan="1" align="center">p-value</th><th rowspan="1" colspan="1" align="center">OR<sup>1</sup></th><th rowspan="1" colspan="1" align="center">p-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" align="left">White</td><td rowspan="1" colspan="1" align="center">0.77</td><td rowspan="1" colspan="1" align="center">0.24</td><td rowspan="1" colspan="1" align="center">1.04</td><td rowspan="1" colspan="1" align="center">0.89</td><td rowspan="1" colspan="1" align="center">1.15</td><td rowspan="1" colspan="1" align="center">0.43</td></tr><tr><td rowspan="1" colspan="1" align="left">Black</td><td rowspan="1" colspan="1" align="center">1.60</td><td rowspan="1" colspan="1" align="center">0.12</td><td rowspan="1" colspan="1" align="center">1.88</td><td rowspan="1" colspan="1" align="center">0.03</td><td rowspan="1" colspan="1" align="center">1.22</td><td rowspan="1" colspan="1" align="center">0.38</td></tr><tr><td rowspan="1" colspan="1" align="left">Hispanic</td><td rowspan="1" colspan="1" align="center">0.42</td><td rowspan="1" colspan="1" align="center">0.08</td><td rowspan="1" colspan="1" align="center">1.02</td><td rowspan="1" colspan="1" align="center">0.97</td><td rowspan="1" colspan="1" align="center">0.94</td><td rowspan="1" colspan="1" align="center">0.87</td></tr><tr><td rowspan="1" colspan="1" align="left">Meta-analysis</td><td rowspan="1" colspan="1" align="center">0.90</td><td rowspan="1" colspan="1" align="center">0.53</td><td rowspan="1" colspan="1" align="center">1.31</td><td rowspan="1" colspan="1" align="center">0.13</td><td rowspan="1" colspan="1" align="center">1.15</td><td rowspan="1" colspan="1" align="center">0.30</td></tr></tbody></table></div><div id="largeobj_idm140660830859536" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4387236/table/T2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN3"><sup>1</sup>Odds ratio (OR) is set such that an OR &gt; 1 indicates a higher genotype frequency in cases compared to controls</div></div></div></div><div id="S16" class="sec sec-last"><h3 id="S16title">Gene set association analysis</h3><p id="P23" class="p p-first-last">We next tested for enrichment of genetic signal across sets of genes important for efavirenz and/or abacavir metabolism and disposition. Per drug, we defined custom sets of 147 (efavirenz) and 99 (abacavir) absorption, distribution, metabolism, and excretion (ADME) genes from the literature based on their importance to drug metabolism (<a href="#SD2" rid="SD2" class=" supplementary-material">Table S1</a>). We used MAGENTA to assess the statistical enrichment of signal in these genes sets against a permuted null distribution. There was no evidence for association in cumulative variation across these gene sets with any of the phenotypes under study (<a href="/pmc/articles/PMC4387236/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). Similarly, there was no evidence for enrichment of association signal in a discovery screen using canonical pathways defined by several databases (Ingenuity, KEGG, GO).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T3"><h3>Table 3</h3><!--caption a7--><div class="caption"><p id="P49">Association results (p-values) for gene set enrichment analysis of an impact of genetic variation in selected ADME genes on virologic response categories</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140660830084064" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" align="left"></th><th colspan="3" rowspan="1" align="center">Efavirenz</th><th colspan="3" rowspan="1" align="center">Abacavir</th></tr><tr><th rowspan="1" colspan="1" align="left"></th><th rowspan="1" colspan="1" align="center">Suppression<br>at 16 weeks</th><th rowspan="1" colspan="1" valign="bottom" align="center">Rebound</th><th rowspan="1" colspan="1" align="center">Suppression<br>at 48 weeks</th><th rowspan="1" colspan="1" align="center">Suppression<br>at 16 weeks</th><th rowspan="1" colspan="1" valign="bottom" align="center">Rebound</th><th rowspan="1" colspan="1" align="center">Suppression<br>at 48 weeks</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" align="left">White</td><td rowspan="1" colspan="1" align="center">0.23</td><td rowspan="1" colspan="1" align="center">0.77</td><td rowspan="1" colspan="1" align="center">0.23</td><td rowspan="1" colspan="1" align="center">0.25</td><td rowspan="1" colspan="1" align="center">0.99</td><td rowspan="1" colspan="1" align="center">0.47</td></tr><tr><td rowspan="1" colspan="1" align="left">Black</td><td rowspan="1" colspan="1" align="center">0.82</td><td rowspan="1" colspan="1" align="center">0.41</td><td rowspan="1" colspan="1" align="center">0.62</td><td rowspan="1" colspan="1" align="center">0.13</td><td rowspan="1" colspan="1" align="center">0.42</td><td rowspan="1" colspan="1" align="center">0.96</td></tr><tr><td rowspan="1" colspan="1" align="left">Hispanic</td><td rowspan="1" colspan="1" align="center">0.81</td><td rowspan="1" colspan="1" align="center">0.51</td><td rowspan="1" colspan="1" align="center">0.33</td><td rowspan="1" colspan="1" align="center">0.83</td><td rowspan="1" colspan="1" align="center">0.74</td><td rowspan="1" colspan="1" align="center">0.84</td></tr><tr><td rowspan="1" colspan="1" align="left">Meta-analysis</td><td rowspan="1" colspan="1" align="center">0.61</td><td rowspan="1" colspan="1" align="center">0.73</td><td rowspan="1" colspan="1" align="center">0.55</td><td rowspan="1" colspan="1" align="center">0.50</td><td rowspan="1" colspan="1" align="center">0.91</td><td rowspan="1" colspan="1" align="center">0.99</td></tr></tbody></table></div><div id="largeobj_idm140660830084064" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC4387236/table/T3/?report=objectonly">Open in a separate window</a></div></div></div></div><div id="S17" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S17title">Discussion</h2><p id="P24" class="p p-first">Efavirenz and abacavir are antiretroviral agents that are often included as components of recommended first-line regimens for human immunodeficiency virus (HIV)-1 infection [<a href="#R1" rid="R1" class=" bibr popnode">1</a>], based on data from multiple prospective, randomized clinical trials [<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370825">2</a>–<a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370787">9</a>, <a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370800">29</a>–<a href="#R31" rid="R31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370809">31</a>, <a href="#R41" rid="R41" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370793">41</a>, <a href="#R42" rid="R42" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370810">42</a>]. Interindividual variability in virologic efficacy of HIV-1 treatment responses may be influenced to polymorphisms in drug absorption, distribution, metabolism, and elimination (ADME) genes as well as off-target genes. We used a genome-wide approach to investigate associations between common human genetic variants and virologic responses to initial regimens that included efavirenz or abacavir. No polymorphism achieved genome-wide significance, either considering the entire genome, on in analyses focused on numerous ADME genes relevant to efavirenz or abacavir. In addition we did not find associations with the <em>CYP2B6</em> genotype that is known to predict the lowest stratum of plasma efavirenz exposure [<a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370796">19</a>].</p><p id="P25">In an effort to capture different underlying aspects of virologic response we separately analyzed based on three different virologic response phenotypes. The first definition, virologic response to HIV-1 RNA &lt;50 copies/mL at ≤16 weeks, was chosen to capture genetic effects on antiretroviral potency while shortening the window of opportunity for confounding by non-adherence. The second definition, virologic relapse to HIV-1 RNA &gt;200 copies/mL after being &lt;200 copies/mL, was chosen to capture possible genetic effects on reducing durability of virologic control. The third definition, virologic response to HIV-1 RNA &lt;50 copies/mL at 48 weeks, was chosen to reflect a more standard definition of virologic response. Lack of association with any of these phenotypes reinforces that there is not a single strong genetic predictor of virologic response for efavirenz or abacavir in the total population. Importantly, these results didn’t change when further restricting to the analyses to further limit the impact of missed doses of treatment.</p><p id="P26">Prospective, randomized clinical trials data offer a unique window to genetic associations, but it is possible that true genetic influences on virologic response to efavirenz and/or abacavir were missed by our GWAS. Our sample size was modest compared to many GWAS of complex traits. We were limited to detecting common variants (&gt;1%) with relatively large effect sizes (in most cases OR &gt; 2). However, associations with drug ADME and off-target genes may have large effect sizes, so may be apparent with small sample sizes. For example, genetic prediction of abacavir hypersensitivity is genome-wide significant (P&lt;5.0×10<sup>−8</sup>) with 15 cases and 200 controls [<a href="#R43" rid="R43" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370837">43</a>], hepatitis C treatment response with 303 cases [<a href="#R44" rid="R44" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370832">44</a>], statin response with 85 cases and 90 controls [<a href="#R45" rid="R45" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370791">45</a>], nevirapine rash with 71 cases and 77 controls [<a href="#R46" rid="R46" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370827">46</a>], and tamoxifen response with 240 cases [<a href="#R47" rid="R47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370806">47</a>].</p><p id="P27">A challenge in quantifying the impact of human genetics on HIV treatment response is that associations are often context-dependent. For example, an association between HLA type and nevirapine hypersensitivity reaction is only seen with high pre-treatment CD4 T-cells counts [<a href="#R48" rid="R48" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370843">48</a>]. In <em>CYP2B6</em> slow metabolizers, a paradoxical association between concomitant rifampicin and increased plasma efavirenz concentrations is only seen with concomitant isoniazid [<a href="#R49" rid="R49" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_781838407">49</a>]. An association between <em>UGT1A1</em> genotype and elevated indirect hyperbilirubinemia with atazanavir/ritonavir is exacerbated by higher pre-treatment bilirubin and hemoglobin concentrations [<a href="#R50" rid="R50" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_441370799">50</a>]. Additionally, the variable efficacy of different regimens may also impact overall virologic outcome. In this study, we addressed this by adjusting for concomitant medication and pre-treatment clinical markers in our association tests. However, directed analysis per-regimen may be necessary to uncover subtle genetic signals masked in such a pooled analysis. Thus, associations with virologic response to efavirenz or abacavir may only be detected when considering appropriate covariables.</p><p id="P28">The impact of human genetic variants of virologic failure with efavirenz and/or abacavir containing regimens may be masked by non-adherence and other non-genetic factors. For example, in the seminal study that identified an association between <em>IL28</em> genotype and virologic response to therapy for hepatitis C virus, removing non-adherent subjects yielded a substantial improvement in power for detection of associated variants [J Fellay, personal communication]. Analyses that can control for important confounders will increase power to detect associations with antiretroviral drugs.</p><p id="P29" class="p p-last">Access to safe and effective antiretroviral therapy is a cornerstone in the global struggle against HIV/AIDS, which now affects ~35 million worldwide. Because suboptimal treatment response can have devastating consequences, it is critical to continue efforts to define the predictive value of human genetics for HIV treatment efficacy and toxicity.</p></div><div id="SM" class="tsec sec"><a id="supplementary-material-sec"></a><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="SMtitle">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><h4>1</h4><div class="sup-box half_rhythm" id="d36e680"><a href="/pmc/articles/PMC4387236/bin/NIHMS668995-supplement-1.doc" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(124K, doc)</sup></div></div><div class="sec suppmat" id="SD2"><h4>2</h4><div class="sup-box half_rhythm" id="d36e684"><a href="/pmc/articles/PMC4387236/bin/NIHMS668995-supplement-2.doc" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(123K, doc)</sup></div></div></div><div id="S18" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S18title">ACKNOWLEDGMENTS</h2><div class="sec"><p id="P34">The authors are grateful to the many persons with HIV infection who volunteered for ACTG384, A5095, A5142, A5202 and A5128. In addition, they acknowledge the contributions of study teams and site staff for these protocols. This project was supported by Award Number U01AI068636 from the National Institute of Allergy and Infectious Diseases and supported by National Institute of Mental Health (NIMH), National Institute of Dental and Craniofacial Research (NIDCR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.</p><p id="P35">Grant support included AI-077505, TR-000445, AI-54999 (DWH), UL1 TR000457 (RMG), AI 064086 (K24 to RHH), AI 36214 (CFAR Clinical Investigation and Biostatistics Core). Study drugs were provided by Bristol-Myers Squibb Company (Princeton, NJ), Gilead Sciences (Gilead Sciences, Inc., Foster City, CA), GlaxoSmithKline, Inc (Research Triangle Park, NC), and Boehringer Ingelheim (Ridgefield, CT).</p><p id="P36">Clinical Research Sites that participated in ACTG protocols ACTG 384, A5095, A5142, or A5202, and collected DNA under protocol A5128, were supported by the following grants from NIH National Institute of Allergy and Infectious Diseases (NIAID): AI-069532, AI-069484, AI-069432, AI-069450, AI-069495, AI-069434, AI-069424, AI-069439, AI-069467, AI-069423, AI-069513, AI-069477, AI-069465, AI-069419, AI-069502, AI-069474, AI-069472, AI-069501, AI-069418, AI-069494, AI-069471, AI-069511, AI-069452, AI-069428, AI-069556, AI-069415, AI-032782, AI-046376, AI-046370, AI-038858, AI-034853, AI-027661, AI-025859, AI-069470, AI-027675, AI-073961, AI-050410, AI-045008, AI-050409, AI-072626, AI-069447, AI-027658, AI-027666, AI-058740, AI-068634 and AI-025868, and by the following grants from NIH National Center for Research Resources (NCRR): RR-000046, RR-000425, RR-025747, RR-025777, RR-025780, RR-024996, RR-024160, RR-023561, RR-024156, RR-024160, and RR-024160.</p><p id="P37">David W. Haas has been principal investigator on a research grant to Vanderbilt from Merck, and has been a consultant to Merck.</p><p id="P38">Eric S. Daar has received research grants from Bristol Myers Squibb, Abbott, Merck, Pfizer, ViiV, Gilead and a consultant/advisor to Bristol Myers Squibb, Merck, ViiV and Gilead.</p><p id="P39">Roy M. Gulick served as a co-investigator on research grants to research grants to Cornell from GlaxoSmitKline, Janssen, Pfizer, and ViiV.</p><p id="P40">Richard H. Haubrich has received honoraria or consultant fees from Gilead Sciences, GSK and Janssen. He also reports research support (to UCSD) from Abbott, GlaxoSmithKline, Merck and Pfizer.</p><p id="P41">Gregory K. Robbins has received research support from Gilead.</p></div></div><div id="idm140660833250832" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140660833250832title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="FN1"> </p><p id="P30" class="p p-first"><strong>Potential conflicts:</strong></p><p id="P31" class="p p-last">Other authors declare no potential conflicts.</p><p></p><p class="fn sec" id="FN2"></p><p id="P32" class="p p-first"><strong>Previous presentation:</strong></p><p id="P33" class="p p-last">Some of these data were presented in 2011 at 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February. Abstract N-153.</p><p></p></div></div><div id="idm140660825077712" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140660825077712title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="element-citation">The_Panel_on_Clinical_Practices_for_Treatment_of_HIV_Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.  [Accessed October 8, 2014, Updated May 1, 2014];<span></span> Available at:  <a href="http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf</a>.</span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="element-citation">Gulick RM, Ribaudo HJ, Shikuma CM, et al.  Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. <span><span class="ref-journal">JAMA. </span>2006;<span class="ref-vol">296</span>(7):769–781.</span> [<a href="/pubmed/16905783" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Three-+vs+four-drug+antiretroviral+regimens+for+the+initial+treatment+of+HIV-1+infection:+a+randomized+controlled+trial&amp;author=RM+Gulick&amp;author=HJ+Ribaudo&amp;author=CM+Shikuma&amp;volume=296&amp;issue=7&amp;publication_year=2006&amp;pages=769-781&amp;pmid=16905783&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="element-citation">Gallant JE, DeJesus E, Arribas JR, et al.  Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. <span><span class="ref-journal">N Engl J Med. </span>2006;<span class="ref-vol">354</span>(3):251–260.</span> [<a href="/pubmed/16421366" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Tenofovir+DF,+emtricitabine,+and+efavirenz+vs.+zidovudine,+lamivudine,+and+efavirenz+for+HIV&amp;author=JE+Gallant&amp;author=E+DeJesus&amp;author=JR+Arribas&amp;volume=354&amp;issue=3&amp;publication_year=2006&amp;pages=251-260&amp;pmid=16421366&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="element-citation">Riddler SA, Haubrich R, DiRienzo AG, et al.  Class-sparing regimens for initial treatment of HIV-1 infection. <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">358</span>(20):2095–2106.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3885902/">PMC free article</a>]</span> [<a href="/pubmed/18480202" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Class-sparing+regimens+for+initial+treatment+of+HIV-1+infection&amp;author=SA+Riddler&amp;author=R+Haubrich&amp;author=AG+DiRienzo&amp;volume=358&amp;issue=20&amp;publication_year=2008&amp;pages=2095-2106&amp;pmid=18480202&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="element-citation">Lennox JL, DeJesus E, Lazzarin A, et al.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. <span><span class="ref-journal">Lancet. </span>2009;<span class="ref-vol">374</span>(9692):796–806.</span> [<a href="/pubmed/19647866" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Safety+and+efficacy+of+raltegravir-based+versus+efavirenz-based+combination+therapy+in+treatment-naive+patients+with+HIV-1+infection:+a+multicentre,+double-blind+randomised+controlled+trial&amp;author=JL+Lennox&amp;author=E+DeJesus&amp;author=A+Lazzarin&amp;volume=374&amp;issue=9692&amp;publication_year=2009&amp;pages=796-806&amp;pmid=19647866&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="element-citation">Cooper DA, Heera J, Goodrich J, et al.  Maraviroc versus Efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. <span><span class="ref-journal">J Infect Dis. </span>2010;<span class="ref-vol">201</span>(6):803–813.</span> [<a href="/pubmed/20151839" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Maraviroc+versus+Efavirenz,+both+in+combination+with+zidovudine-lamivudine,+for+the+treatment+of+antiretroviral-naive+subjects+with+CCR5-tropic+HIV-1+infection&amp;author=DA+Cooper&amp;author=J+Heera&amp;author=J+Goodrich&amp;volume=201&amp;issue=6&amp;publication_year=2010&amp;pages=803-813&amp;pmid=20151839&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="element-citation">Daar ES, Tierney C, Fischl MA, et al.  Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. <span><span class="ref-journal">Ann Intern Med. </span>2011;<span class="ref-vol">154</span>(7):445–456.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3430716/">PMC free article</a>]</span> [<a href="/pubmed/21320923" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Intern+Med&amp;title=Atazanavir+plus+ritonavir+or+efavirenz+as+part+of+a+3-drug+regimen+for+initial+treatment+of+HIV-1&amp;author=ES+Daar&amp;author=C+Tierney&amp;author=MA+Fischl&amp;volume=154&amp;issue=7&amp;publication_year=2011&amp;pages=445-456&amp;pmid=21320923&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="element-citation">Sax PE, DeJesus E, Mills A, et al.  Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. <span><span class="ref-journal">Lancet. </span>2012;<span class="ref-vol">379</span>(9835):2439–2448.</span> [<a href="/pubmed/22748591" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Co-formulated+elvitegravir,+cobicistat,+emtricitabine,+and+tenofovir+versus+co-formulated+efavirenz,+emtricitabine,+and+tenofovir+for+initial+treatment+of+HIV-1+infection:+a+randomised,+double-blind,+phase+3+trial,+analysis+of+results+after+48+weeks&amp;author=PE+Sax&amp;author=E+DeJesus&amp;author=A+Mills&amp;volume=379&amp;issue=9835&amp;publication_year=2012&amp;pages=2439-2448&amp;pmid=22748591&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="element-citation">Cohen CJ, Molina JM, Cahn P, et al.  Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. <span><span class="ref-journal">JAIDS. </span>2012;<span class="ref-vol">60</span>(1):33–42.</span> [<a href="/pubmed/22343174" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAIDS&amp;title=Efficacy+and+safety+of+rilpivirine+(TMC278)+versus+efavirenz+at+48+weeks+in+treatment-naive+HIV-1-infected+patients:+pooled+results+from+the+phase+3+double-blind+randomized+ECHO+and+THRIVE+Trials&amp;author=CJ+Cohen&amp;author=JM+Molina&amp;author=P+Cahn&amp;volume=60&amp;issue=1&amp;publication_year=2012&amp;pages=33-42&amp;pmid=22343174&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="element-citation">Fellay J, Marzolini C, Meaden ER, et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. <span><span class="ref-journal">Lancet. </span>2002;<span class="ref-vol">359</span>(9300):30–36.</span> [<a href="/pubmed/11809184" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Response+to+antiretroviral+treatment+in+HIV-1-infected+individuals+with+allelic+variants+of+the+multidrug+resistance+transporter+1:+a+pharmacogenetics+study&amp;author=J+Fellay&amp;author=C+Marzolini&amp;author=ER+Meaden&amp;volume=359&amp;issue=9300&amp;publication_year=2002&amp;pages=30-36&amp;pmid=11809184&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="element-citation">Ribaudo HJ, Liu H, Schwab M, et al.  Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. <span><span class="ref-journal">J Infect Dis. </span>2010;<span class="ref-vol">202</span>(5):717–722.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2919241/">PMC free article</a>]</span> [<a href="/pubmed/20662624" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Effect+of+CYP2B6,+ABCB1,+and+CYP3A5+polymorphisms+on+efavirenz+pharmacokinetics+and+treatment+response:+an+AIDS+Clinical+Trials+Group+study&amp;author=HJ+Ribaudo&amp;author=H+Liu&amp;author=M+Schwab&amp;volume=202&amp;issue=5&amp;publication_year=2010&amp;pages=717-722&amp;pmid=20662624&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="element-citation">Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. <span><span class="ref-journal">J Pharmacol Exp Ther. </span>2003;<span class="ref-vol">306</span>(1):287–300.</span> [<a href="/pubmed/12676886" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Pharmacol+Exp+Ther&amp;title=The+cytochrome+P450+2B6+(CYP2B6)+is+the+main+catalyst+of+efavirenz+primary+and+secondary+metabolism:+implication+for+HIV/AIDS+therapy+and+utility+of+efavirenz+as+a+substrate+marker+of+CYP2B6+catalytic+activity&amp;author=BA+Ward&amp;author=JC+Gorski&amp;author=DR+Jones&amp;author=SD+Hall&amp;author=DA+Flockhart&amp;volume=306&amp;issue=1&amp;publication_year=2003&amp;pages=287-300&amp;pmid=12676886&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="element-citation">Haas DW, Severe P, Jean Juste MA, Pape JW, Fitzgerald DW. Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti. <span><span class="ref-journal">J Antimicrob Chemother. </span>2014</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4100704/">PMC free article</a>]</span> [<a href="/pubmed/24695352" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Antimicrob+Chemother&amp;title=Functional+CYP2B6+variants+and+virologic+response+to+an+efavirenz-containing+regimen+in+Port-au-Prince,+Haiti&amp;author=DW+Haas&amp;author=P+Severe&amp;author=MA+Jean+Juste&amp;author=JW+Pape&amp;author=DW+Fitzgerald&amp;publication_year=2014&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="element-citation">Haas DW, Ribaudo HJ, Kim RB, et al.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. <span><span class="ref-journal">AIDS. </span>2004;<span class="ref-vol">18</span>(18):2391–2400.</span> [<a href="/pubmed/15622315" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AIDS&amp;title=Pharmacogenetics+of+efavirenz+and+central+nervous+system+side+effects:+an+Adult+AIDS+Clinical+Trials+Group+study&amp;author=DW+Haas&amp;author=HJ+Ribaudo&amp;author=RB+Kim&amp;volume=18&amp;issue=18&amp;publication_year=2004&amp;pages=2391-2400&amp;pmid=15622315&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="element-citation">Tsuchiya K, Gatanaga H, Tachikawa N, et al.  Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2004;<span class="ref-vol">319</span>(4):1322–1326.</span> [<a href="/pubmed/15194512" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Biophys+Res+Commun&amp;title=Homozygous+CYP2B6+*6+(Q172H+and+K262R)+correlates+with+high+plasma+efavirenz+concentrations+in+HIV-1+patients+treated+with+standard+efavirenz-containing+regimens&amp;author=K+Tsuchiya&amp;author=H+Gatanaga&amp;author=N+Tachikawa&amp;volume=319&amp;issue=4&amp;publication_year=2004&amp;pages=1322-1326&amp;pmid=15194512&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="element-citation">Rotger M, Colombo S, Furrer H, et al.  Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. <span><span class="ref-journal">Pharmacogenet Genom. </span>2005;<span class="ref-vol">15</span>(1):1–5.</span> [<a href="/pubmed/15864119" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenet+Genom&amp;title=Influence+of+CYP2B6+polymorphism+on+plasma+and+intracellular+concentrations+and+toxicity+of+efavirenz+and+nevirapine+in+HIV-infected+patients&amp;author=M+Rotger&amp;author=S+Colombo&amp;author=H+Furrer&amp;volume=15&amp;issue=1&amp;publication_year=2005&amp;pages=1-5&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="element-citation">Haas DW, Smeaton LM, Shafer RW, et al.  Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group Study. <span><span class="ref-journal">J Infect Dis. </span>2005;<span class="ref-vol">192</span>(11):1931–1942.</span> [<a href="/pubmed/16267764" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Pharmacogenetics+of+long-term+responses+to+antiretroviral+regimens+containing+efavirenz+and/or+nelfinavir:+an+Adult+AIDS+Clinical+Trials+Group+Study&amp;author=DW+Haas&amp;author=LM+Smeaton&amp;author=RW+Shafer&amp;volume=192&amp;issue=11&amp;publication_year=2005&amp;pages=1931-1942&amp;pmid=16267764&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="element-citation">Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Influence of 516G&gt;T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. <span><span class="ref-journal">Clin Infect Dis. </span>2005;<span class="ref-vol">40</span>(9):1358–1361.</span> [<a href="/pubmed/15825040" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Infect+Dis&amp;title=Influence+of+516G>T+polymorphisms+at+the+gene+encoding+the+CYP450-2B6+isoenzyme+on+efavirenz+plasma+concentrations+in+HIV-infected+subjects&amp;author=S+Rodriguez-Novoa&amp;author=P+Barreiro&amp;author=A+Rendon&amp;author=I+Jimenez-Nacher&amp;author=J+Gonzalez-Lahoz&amp;volume=40&amp;issue=9&amp;publication_year=2005&amp;pages=1358-1361&amp;pmid=15825040&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="element-citation">Holzinger ER, Grady B, Ritchie MD, et al.  Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. <span><span class="ref-journal">Pharmacogenet Genom. </span>2012;<span class="ref-vol">22</span>(12):858–867.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3614365/">PMC free article</a>]</span> [<a href="/pubmed/23080225" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenet+Genom&amp;title=Genome-wide+association+study+of+plasma+efavirenz+pharmacokinetics+in+AIDS+Clinical+Trials+Group+protocols+implicates+several+CYP2B6+variants&amp;author=ER+Holzinger&amp;author=B+Grady&amp;author=MD+Ritchie&amp;volume=22&amp;issue=12&amp;publication_year=2012&amp;pages=858-867&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="element-citation">Wyen C, Hendra H, Vogel M, et al.  Impact of CYP2B6 983T&gt;C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. <span><span class="ref-journal">J Antimicrob Chemo. </span>2008;<span class="ref-vol">61</span>(4):914–918.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3596857/">PMC free article</a>]</span> [<a href="/pubmed/18281305" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Antimicrob+Chemo&amp;title=Impact+of+CYP2B6+983T>C+polymorphism+on+non-nucleoside+reverse+transcriptase+inhibitor+plasma+concentrations+in+HIV-infected+patients&amp;author=C+Wyen&amp;author=H+Hendra&amp;author=M+Vogel&amp;volume=61&amp;issue=4&amp;publication_year=2008&amp;pages=914-918&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="element-citation">Wang J, Sonnerborg A, Rane A, et al.  Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. <span><span class="ref-journal">Pharmacogenet Genom. </span>2006;<span class="ref-vol">16</span>(3):191–198.</span> [<a href="/pubmed/16495778" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenet+Genom&amp;title=Identification+of+a+novel+specific+CYP2B6+allele+in+Africans+causing+impaired+metabolism+of+the+HIV+drug+efavirenz&amp;author=J+Wang&amp;author=A+Sonnerborg&amp;author=A+Rane&amp;volume=16&amp;issue=3&amp;publication_year=2006&amp;pages=191-198&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="element-citation">dbSNP - Short Genetic Variations.  [Accessed 9/12/2011];<span></span> Available at:  <a href="http://www.ncbi.nlm.nih.gov/projects/SNP/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.ncbi.nlm.nih.gov/projects/SNP/</a></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="element-citation">Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ., Jr Population pharmacokinetic meta-analysis with efavirenz. <span><span class="ref-journal">Int J Clin Pharmacol Ther. </span>2002;<span class="ref-vol">40</span>(11):507–519.</span> [<a href="/pubmed/12698988" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Clin+Pharmacol+Ther&amp;title=Population+pharmacokinetic+meta-analysis+with+efavirenz&amp;author=JS+Barrett&amp;author=AS+Joshi&amp;author=M+Chai&amp;author=TM+Ludden&amp;author=WD+Fiske&amp;volume=40&amp;issue=11&amp;publication_year=2002&amp;pages=507-519&amp;pmid=12698988&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="element-citation">Pfister M, Labbe L, Hammer SM, et al.  Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. <span><span class="ref-journal">Antimicrob Agents Chemother. </span>2003;<span class="ref-vol">47</span>(1):130–137.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC148981/">PMC free article</a>]</span> [<a href="/pubmed/12499180" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Antimicrob+Agents+Chemother&amp;title=Population+pharmacokinetics+and+pharmacodynamics+of+efavirenz,+nelfinavir,+and+indinavir:+Adult+AIDS+Clinical+Trial+Group+Study+398&amp;author=M+Pfister&amp;author=L+Labbe&amp;author=SM+Hammer&amp;volume=47&amp;issue=1&amp;publication_year=2003&amp;pages=130-137&amp;pmid=12499180&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="element-citation">Ziagen (abacavir sulfate) full prescribing information.  [Accessed May 9];<span></span> Available at:  <a href="http://www.viivhealthcare.com/gskprm/htdocs/documents/ZIAGEN-PI-MG.PDF" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.viivhealthcare.com/gskprm/htdocs/documents/ZIAGEN-PI-MG.PDF</a>. <span class="nowrap">[<a href="https://scholar.google.com/scholar?q=Ziagen+(abacavir+sulfate)+full+prescribing+information+Accessed+May+9+Available+at:++http://www.viivhealthcare.com/gskprm/htdocs/documents/ZIAGEN-PI-MG.PDF+" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="element-citation">Mallal S, Nolan D, Witt C, et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. <span><span class="ref-journal">Lancet. </span>2002;<span class="ref-vol">359</span>(9308):727–732.</span> [<a href="/pubmed/11888582" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Association+between+presence+of+HLA-B*5701,+HLA-DR7,+and+HLA-DQ3+and+hypersensitivity+to+HIV-1+reverse-transcriptase+inhibitor+abacavir&amp;author=S+Mallal&amp;author=D+Nolan&amp;author=C+Witt&amp;volume=359&amp;issue=9308&amp;publication_year=2002&amp;pages=727-732&amp;pmid=11888582&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="element-citation">Hetherington S, Hughes AR, Mosteller M, et al.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. <span><span class="ref-journal">Lancet. </span>2002;<span class="ref-vol">359</span>(9312):1121–1122.</span> [<a href="/pubmed/11943262" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Genetic+variations+in+HLA-B+region+and+hypersensitivity+reactions+to+abacavir&amp;author=S+Hetherington&amp;author=AR+Hughes&amp;author=M+Mosteller&amp;volume=359&amp;issue=9312&amp;publication_year=2002&amp;pages=1121-1122&amp;pmid=11943262&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="element-citation">Mallal S, Phillips E, Carosi G, et al.  HLA-B*5701 screening for hypersensitivity to abacavir. <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">358</span>(6):568–579.</span> [<a href="/pubmed/18256392" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=HLA-B*5701+screening+for+hypersensitivity+to+abacavir&amp;author=S+Mallal&amp;author=E+Phillips&amp;author=G+Carosi&amp;volume=358&amp;issue=6&amp;publication_year=2008&amp;pages=568-579&amp;pmid=18256392&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="element-citation">Sax PE, Tierney C, Collier AC, et al.  Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. <span><span class="ref-journal">N Engl J Med. </span>2009;<span class="ref-vol">361</span>(23):2230–2240.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2800041/">PMC free article</a>]</span> [<a href="/pubmed/19952143" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Abacavir-lamivudine+versus+tenofovir-emtricitabine+for+initial+HIV-1+therapy&amp;author=PE+Sax&amp;author=C+Tierney&amp;author=AC+Collier&amp;volume=361&amp;issue=23&amp;publication_year=2009&amp;pages=2230-2240&amp;pmid=19952143&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30. <span class="element-citation">Smith KY, Patel P, Fine D, et al.  Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. <span><span class="ref-journal">AIDS. </span>2009;<span class="ref-vol">23</span>(12):1547–1556.</span> [<a href="/pubmed/19542866" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AIDS&amp;title=Randomized,+double-blind,+placebo-matched,+multicenter+trial+of+abacavir/lamivudine+or+tenofovir/emtricitabine+with+lopinavir/ritonavir+for+initial+HIV+treatment&amp;author=KY+Smith&amp;author=P+Patel&amp;author=D+Fine&amp;volume=23&amp;issue=12&amp;publication_year=2009&amp;pages=1547-1556&amp;pmid=19542866&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31. <span class="element-citation">Walmsley SL, Antela A, Clumeck N, et al.  Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. <span><span class="ref-journal">N Engl J Med. </span>2013;<span class="ref-vol">369</span>(19):1807–1818.</span> [<a href="/pubmed/24195548" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Dolutegravir+plus+abacavir-lamivudine+for+the+treatment+of+HIV-1+infection&amp;author=SL+Walmsley&amp;author=A+Antela&amp;author=N+Clumeck&amp;volume=369&amp;issue=19&amp;publication_year=2013&amp;pages=1807-1818&amp;pmid=24195548&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">32. <span class="element-citation">Robbins GK, De GV, Shafer RW, et al.  Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. <span><span class="ref-journal">N Engl J Med. </span>2003;<span class="ref-vol">349</span>(24):2293–2303.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4767257/">PMC free article</a>]</span> [<a href="/pubmed/14668455" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Comparison+of+sequential+three-drug+regimens+as+initial+therapy+for+HIV-1+infection&amp;author=GK+Robbins&amp;author=GV+De&amp;author=RW+Shafer&amp;volume=349&amp;issue=24&amp;publication_year=2003&amp;pages=2293-2303&amp;pmid=14668455&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R33">33. <span class="element-citation">Shafer RW, Smeaton LM, Robbins GK, et al.  Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. <span><span class="ref-journal">N Engl J Med. </span>2003;<span class="ref-vol">349</span>(24):2304–2315.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4768873/">PMC free article</a>]</span> [<a href="/pubmed/14668456" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Comparison+of+four-drug+regimens+and+pairs+of+sequential+three-drug+regimens+as+initial+therapy+for+HIV-1+infection&amp;author=RW+Shafer&amp;author=LM+Smeaton&amp;author=GK+Robbins&amp;volume=349&amp;issue=24&amp;publication_year=2003&amp;pages=2304-2315&amp;pmid=14668456&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R34">34. <span class="element-citation">Haas DW, Wilkinson GR, Kuritzkes DR, et al.  A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. <span><span class="ref-journal">HIV Clin Trials. </span>2003;<span class="ref-vol">4</span>(5):287–300.</span> [<a href="/pubmed/14583845" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=HIV+Clin+Trials&amp;title=A+multi-investigator/institutional+DNA+bank+for+AIDS-related+human+genetic+studies:+AACTG+Protocol+A5128&amp;author=DW+Haas&amp;author=GR+Wilkinson&amp;author=DR+Kuritzkes&amp;volume=4&amp;issue=5&amp;publication_year=2003&amp;pages=287-300&amp;pmid=14583845&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R35">35. <span class="element-citation">Pereyra F, Jia X, McLaren PJ, et al.  The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. <span><span class="ref-journal">Science. </span>2010;<span class="ref-vol">330</span>(6010):1551–1557.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3235490/">PMC free article</a>]</span> [<a href="/pubmed/21051598" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=The+major+genetic+determinants+of+HIV-1+control+affect+HLA+class+I+peptide+presentation&amp;author=F+Pereyra&amp;author=X+Jia&amp;author=PJ+McLaren&amp;volume=330&amp;issue=6010&amp;publication_year=2010&amp;pages=1551-1557&amp;pmid=21051598&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R36">36. <span class="element-citation">Purcell S, Neale B, Todd-Brown K, et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">81</span>(3):559–575.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1950838/">PMC free article</a>]</span> [<a href="/pubmed/17701901" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Hum+Genet&amp;title=PLINK:+a+tool+set+for+whole-genome+association+and+population-based+linkage+analyses&amp;author=S+Purcell&amp;author=B+Neale&amp;author=K+Todd-Brown&amp;volume=81&amp;issue=3&amp;publication_year=2007&amp;pages=559-575&amp;pmid=17701901&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R37">37. <span class="element-citation">Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. <span><span class="ref-journal">Nature Genet. </span>2006;<span class="ref-vol">38</span>(8):904–909.</span> [<a href="/pubmed/16862161" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Genet&amp;title=Principal+components+analysis+corrects+for+stratification+in+genome-wide+association+studies&amp;author=AL+Price&amp;author=NJ+Patterson&amp;author=RM+Plenge&amp;author=ME+Weinblatt&amp;author=NA+Shadick&amp;volume=38&amp;issue=8&amp;publication_year=2006&amp;pages=904-909&amp;pmid=16862161&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R38">38. <span class="element-citation">Browning BL, Browning SR. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. <span><span class="ref-journal">Am J Hum Genet. </span>2009;<span class="ref-vol">84</span>(2):210–223.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2668004/">PMC free article</a>]</span> [<a href="/pubmed/19200528" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Hum+Genet&amp;title=A+unified+approach+to+genotype+imputation+and+haplotype-phase+inference+for+large+data+sets+of+trios+and+unrelated+individuals&amp;author=BL+Browning&amp;author=SR+Browning&amp;volume=84&amp;issue=2&amp;publication_year=2009&amp;pages=210-223&amp;pmid=19200528&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R39">39. <span class="element-citation">Purcell S, Sham PC.  [Accessed May 10];<span></span> Available at:  <a href="http://pngu.mgh.harvard.edu/~purcell/gpc/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://pngu.mgh.harvard.edu/~purcell/gpc/</a> <span class="nowrap">[<a href="https://scholar.google.com/scholar?q=Purcell+S+Sham+PC+Accessed+May+10+Available+at:++http://pngu.mgh.harvard.edu/~purcell/gpc/+" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R40">40. <span class="element-citation">Segre AV, et al.  Consortium D, investigators M. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. <span><span class="ref-journal">PLoS Genet. </span>2010;<span class="ref-vol">6</span>(8)</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2920848/">PMC free article</a>]</span> [<a href="/pubmed/20714348" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Genet&amp;title=Common+inherited+variation+in+mitochondrial+genes+is+not+enriched+for+associations+with+type+2+diabetes+or+related+glycemic+traits&amp;author=AV+Segre&amp;volume=6&amp;issue=8&amp;publication_year=2010&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R41">41. <span class="element-citation">Squires K, Lazzarin A, Gatell JM, et al.  Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. <span><span class="ref-journal">JAIDS. </span>2004;<span class="ref-vol">36</span>(5):1011–1019.</span> [<a href="/pubmed/15247553" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAIDS&amp;title=Comparison+of+once-daily+atazanavir+with+efavirenz,+each+in+combination+with+fixed-dose+zidovudine+and+lamivudine,+as+initial+therapy+for+patients+infected+with+HIV&amp;author=K+Squires&amp;author=A+Lazzarin&amp;author=JM+Gatell&amp;volume=36&amp;issue=5&amp;publication_year=2004&amp;pages=1011-1019&amp;pmid=15247553&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R42">42. <span class="element-citation">van Leth F, Phanuphak P, Ruxrungtham K, et al.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. <span><span class="ref-journal">Lancet. </span>2004;<span class="ref-vol">363</span>(9417):1253–1263.</span> [<a href="/pubmed/15094269" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Comparison+of+first-line+antiretroviral+therapy+with+regimens+including+nevirapine,+efavirenz,+or+both+drugs,+plus+stavudine+and+lamivudine:+a+randomised+open-label+trial,+the+2NN+Study&amp;author=F+van+Leth&amp;author=P+Phanuphak&amp;author=K+Ruxrungtham&amp;volume=363&amp;issue=9417&amp;publication_year=2004&amp;pages=1253-1263&amp;pmid=15094269&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R43">43. <span class="element-citation">Nelson MR, Bacanu SA, Mosteller M, et al.  Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. <span><span class="ref-journal">Pharmacogenom J. </span>2009;<span class="ref-vol">9</span>(1):23–33.</span> [<a href="/pubmed/18301416" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenom+J&amp;title=Genome-wide+approaches+to+identify+pharmacogenetic+contributions+to+adverse+drug+reactions&amp;author=MR+Nelson&amp;author=SA+Bacanu&amp;author=M+Mosteller&amp;volume=9&amp;issue=1&amp;publication_year=2009&amp;pages=23-33&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R44">44. <span class="element-citation">Tanaka Y, Kurosaki M, Nishida N, et al.  Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. <span><span class="ref-journal">Hum Mol Genet. </span>2011;<span class="ref-vol">20</span>(17):3507–3516.</span> [<a href="/pubmed/21659334" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hum+Mol+Genet&amp;title=Genome-wide+association+study+identified+ITPA/DDRGK1+variants+reflecting+thrombocytopenia+in+pegylated+interferon+and+ribavirin+therapy+for+chronic+hepatitis+C&amp;author=Y+Tanaka&amp;author=M+Kurosaki&amp;author=N+Nishida&amp;volume=20&amp;issue=17&amp;publication_year=2011&amp;pages=3507-3516&amp;pmid=21659334&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R45">45. <span class="element-citation">Link E, Parish S, Armitage J, et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">359</span>(8):789–799.</span> [<a href="/pubmed/18650507" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=SLCO1B1+variants+and+statin-induced+myopathy--a+genomewide+study&amp;author=E+Link&amp;author=S+Parish&amp;author=J+Armitage&amp;volume=359&amp;issue=8&amp;publication_year=2008&amp;pages=789-799&amp;pmid=18650507&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R46">46. <span class="element-citation">Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al.  Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. <span><span class="ref-journal">Clin Infect Dis. </span>2011;<span class="ref-vol">53</span>(4):341–348.</span> [<a href="/pubmed/21810746" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Infect+Dis&amp;title=Genome-wide+association+study+identifies+variations+in+6p21.3+associated+with+nevirapine-induced+rash&amp;author=S+Chantarangsu&amp;author=T+Mushiroda&amp;author=S+Mahasirimongkol&amp;volume=53&amp;issue=4&amp;publication_year=2011&amp;pages=341-348&amp;pmid=21810746&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R47">47. <span class="element-citation">Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. <span><span class="ref-journal">Cancer Sci. </span>2008;<span class="ref-vol">99</span>(5):967–972.</span> [<a href="/pubmed/18294295" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Sci&amp;title=Association+of+genetic+polymorphisms+in+SLCO1B3+and+ABCC2+with+docetaxel-induced+leukopenia&amp;author=K+Kiyotani&amp;author=T+Mushiroda&amp;author=M+Kubo&amp;author=H+Zembutsu&amp;author=Y+Sugiyama&amp;volume=99&amp;issue=5&amp;publication_year=2008&amp;pages=967-972&amp;pmid=18294295&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R48">48. <span class="element-citation">Martin AM, Nolan D, James I, et al.  Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. <span><span class="ref-journal">AIDS. </span>2005;<span class="ref-vol">19</span>(1):97–99.</span> [<a href="/pubmed/15627041" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AIDS&amp;title=Predisposition+to+nevirapine+hypersensitivity+associated+with+HLA-DRB1*0101+and+abrogated+by+low+CD4+T-cell+counts&amp;author=AM+Martin&amp;author=D+Nolan&amp;author=I+James&amp;volume=19&amp;issue=1&amp;publication_year=2005&amp;pages=97-99&amp;pmid=15627041&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R49">49. <span class="element-citation">Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. <span><span class="ref-journal">AIDS. </span>2011;<span class="ref-vol">25</span>(3):388–390.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6170200/">PMC free article</a>]</span> [<a href="/pubmed/21150552" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AIDS&amp;title=Paradoxically+elevated+efavirenz+concentrations+in+HIV/tuberculosis-coinfected+patients+with+CYP2B6+516TT+genotype+on+rifampin-containing+antituberculous+therapy&amp;author=A+Kwara&amp;author=M+Lartey&amp;author=KW+Sagoe&amp;author=MH+Court&amp;volume=25&amp;issue=3&amp;publication_year=2011&amp;pages=388-390&amp;pmid=21150552&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R50">50. <span class="element-citation">Johnson DH, Venuto C, Ritchie MD, et al.  Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. <span><span class="ref-journal">Pharmacogenet Genom. </span>2014;<span class="ref-vol">24</span>(4):195–203.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4059003/">PMC free article</a>]</span> [<a href="/pubmed/24557078" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenet+Genom&amp;title=Genomewide+association+study+of+atazanavir+pharmacokinetics+and+hyperbilirubinemia+in+AIDS+Clinical+Trials+Group+protocol+A5202&amp;author=DH+Johnson&amp;author=C+Venuto&amp;author=MD+Ritchie&amp;volume=24&amp;issue=4&amp;publication_year=2014&amp;pages=195-203&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="#ui-ncbiinpagenav-heading-3">Associated Data</a></li><li><a href="#idm140660840931824title">Abstract</a></li><li><a href="#S5title">Introduction</a></li><li><a href="#S6title">Methods</a></li><li><a href="#S13title">Results</a></li><li><a href="#S17title">Discussion</a></li><li><a href="#SMtitle">Supplementary Material</a></li><li><a href="#S18title">ACKNOWLEDGMENTS</a></li><li><a href="#idm140660833250832title">Footnotes</a></li><li><a href="#idm140660825077712title">References</a></li></ul></div></div><!--post-content--></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC4387236/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC4387236/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC4387236/pdf/nihms668995.pdf">PDF (719K)</a></li> | <li><a href="#" data-citationid="PMC4387236" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4387236%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4387236%2F&amp;text=Genome-wide%20Association%20Study%20of%20Virologic%20Response%20with%20Efavirenz-%20or%20Abacavir-containing%20Regimens%20in%20AIDS%20Clinical%20Trials%20Group%20Protocols" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4387236%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="25461247" data-aiid="4387236" data-aid="4387236" data-iid="251462" data-domainid="319" data-domain="nihpa" data-accid="PMC4387236" data-md5="6e63d7903ba2e1b56f580e1e43cebc0f">
<div class="portlet pubmed_favoritesad">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Save items</span></h3></div>
<a name="Shutter" sid="1" href="#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="pmfavad" toggles="ui-portlet_content-5" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-5" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<input name="absid" id="absid" value="4387236" type="hidden"><div id="pubmed_favoritesad" class="empty" data-db="pmc">
<span role="menubar"><div class="ui-ncbisetswitch ltd-hover" role="menuitem" aria-expanded="false" aria-haspopup="true"><a href="/myncbi/collections/" class="jig-ncbisetswitch blind collink ltd-hover ui-ncbisetswitch-hasStar" id="favList" data-jigconfig="destSelector:'#favUL',starExists:true,createCollectionUrl:'#',manageCollectionsUrl:'/myncbi/collections/'"><span class="star"></span>Add to Favorites</a><a class="ui-ncbisetswitch-button ltd-hover" title="View more options" href="#"><span class="ui-icon ui-icon-triangle-1-s ui-ncbisetswitch-down">View more options</span></a></div></span><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu ui-ncbisetswitch-popper"><ul id="favUL" class="ui-ncbisetswitch-options"></ul><ul class="ui-ncbisetswitch-actions"><li class="ui-ncbisetswitch-actions-create" style="display: block;"><a class="ui-ncbisetswitch-create-collection" href="#">Create collection...</a></li><li class="ui-ncbisetswitch-actions-manage" style="display: block;"><a class="ui-ncbisetswitch-manage-collections" href="/myncbi/collections/">Manage collections...</a></li></ul></div>
</div>
<div class="colloading">loading</div>
<span id="submenu_AddToCollections"><form method="post"><input class="button_apply" name="addtocollection" value="1" type="submit"></form></span>
</div></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div>
<a name="Shutter" sid="1" href="#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" toggles="ui-portlet_content-6" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-6" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="/pubmed/18193496" ref="reftype=relart&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.</a><span class="source">[J Acquir Immune Defic Syndr. 2...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-7" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Acquir Immune Defic Syndr. 2007 Dec 15; 46(5):547-54. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="/pubmed/16905783" ref="reftype=relart&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.</a><span class="source">[JAMA. 2006]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-8" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">JAMA. 2006 Aug 16; 296(7):769-81. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="/pubmed/26148204" ref="reftype=relart&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.</a><span class="source">[Pharmacogenet Genomics. 2015]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-9" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wanga V, Venuto C, Morse GD, Acosta EP, Daar ES, Haas DW, Li C, Shepherd BE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pharmacogenet Genomics. 2015 Sep; 25(9):450-61. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="/pubmed/25698454" ref="reftype=relart&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.</a><span class="source">[Drugs. 2015]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-10" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Greig SL, Deeks ED. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs. 2015 Apr; 75(5):503-14. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="/pubmed/19767318" ref="reftype=relart&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Efavirenz: a decade of clinical experience in the treatment of HIV.</a><span class="source">[J Antimicrob Chemother. 2009]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-11" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Maggiolo F. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Antimicrob Chemother. 2009 Nov; 64(5):910-28. Epub 2009 Sep 18.</em>
</div>
</li>
</ul>
<a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=25461247&amp;log%24=relatedreviews&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Reviews&amp;rendering-type=normal">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=25461247&amp;log%24=relatedarticles&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Related%20Records&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Cited by other articles in PMC</span></h3></div>
<a name="Shutter" sid="1" href="#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-12" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-12" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="/pmc/articles/PMC5718358/" ref="reftype=relart&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Efavirenz Therapeutic Range in HIV-1 Treatment Naïve Participants</a><span class="source">[Therapeutic drug monitoring. 2...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-13" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Yang Y, Wilding GE, Morse GD. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Therapeutic drug monitoring. 2017 Dec; 39(6): 596-603</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="/pmc/articles/PMC5537324/" ref="reftype=relart&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Host genetic variation and HIV disease: from mapping to mechanism</a><span class="source">[Immunogenetics. 2017]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-14" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Naranbhai V, Carrington M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Immunogenetics. 2017 Jul 10; 69(8): 489-498</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="/pmc/articles/PMC5524513/" ref="reftype=relart&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">CYP2B6 516G&gt;T Minor Allele Protective of Late Virologic Failure in Efavirenz-treated HIV-Infected Patients in Botswana</a><span class="source">[Journal of acquired immune def...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-15" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Vujkovic M, Bellamy SL, Zuppa AF, Gastonguay M, Moorthy GS, Ratshaa BR, Han X, Steenhoff AP, Mosepele M, Strom BL, Aplenc R, Bisson GP, Gross R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Journal of acquired immune deficiency syndromes (1999). 2017 Aug 1; 75(4): 488-491</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="/pmc/articles/PMC5117918/" ref="reftype=relart&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Role of pharmacogenetics in public health and clinical health care: a SWOT analysis</a><span class="source">[European Journal of Human Gene...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-16" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kapoor R, Tan-Koi WC, Teo YY. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">European Journal of Human Genetics. 2016 Aug 31; 24(12): 1651-1657</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="/pmc/articles/PMC4916189/" ref="reftype=relart&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600&nbsp;mg in Treatment-Naïve HIV-Infected Patients at 96&nbsp;Weeks: Results of the ENCORE1 Study</a><span class="source">[Clinical Pharmacokinetics. 2015]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-17" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clinical Pharmacokinetics. 2015 Dec 29; 55: 861-873</em>
</div>
</li>
</ul>
<a class="seemore" href="citedby/" ref="reftype=relart&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|CitedBy&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Links</span></h3></div>
<a name="Shutter" sid="1" href="#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-18" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-18" aria-hidden="false"><ul>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="/pmc/?Db=pccompound&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pccompound&amp;IdsFromResult=4387236" ref="reftype=Compound&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Compound&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Compound</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-19" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Compound<div class="brieflinkpopdesc">PubChem Compound links</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="/pmc/?Db=medgen&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_medgen&amp;IdsFromResult=4387236" ref="reftype=MedGen&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Unknown%20Link%20Name&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">MedGen</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-20" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">MedGen<div class="brieflinkpopdesc">Related information in MedGen</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="/pubmed/25461247/" ref="reftype=PubMed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|PubMed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">PubMed</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-21" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">PubMed<div class="brieflinkpopdesc">PubMed citations for these articles</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="/pmc/?Db=taxonomy&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_taxonomy&amp;IdsFromResult=4387236" ref="reftype=Taxonomy&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Taxonomy&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Taxonomy</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-22" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Taxonomy<div class="brieflinkpopdesc">Related taxonomy entry</div>
</div>
</li>
</ul></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Recent Activity</span></h3></div>
<a name="Shutter" sid="1" href="#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" toggles="ui-portlet_content-23" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-23" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="">
<div class="action">
<a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a>
</div>
<ul id="activity">
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dd57f8375f66d018fe5e136">Genome-wide Association Study of Virologic Response with Efavirenz- or Abacavir-...</a><div class="ralinkpop offscreen_noflow">Genome-wide Association Study of Virologic Response with Efavirenz- or Abacavir-containing Regimens in AIDS Clinical Trials Group Protocols<div class="brieflinkpopdesc">NIHPA Author Manuscripts. 2015 Feb; 25(2)51</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=2" href="/portal/utils/pageresolver.fcgi?recordid=5dd57f51dde0893a8bd79bd9">A Common variant in RAB27A gene is associated with fractional exhaled nitric oxi...</a><div class="ralinkpop offscreen_noflow">A Common variant in RAB27A gene is associated with fractional exhaled nitric oxide levels in adults<div class="brieflinkpopdesc">NIHPA Author Manuscripts. 2015 Apr; 45(4)797</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=3" href="/portal/utils/pageresolver.fcgi?recordid=5dd57f22dd2142621dc749a4">Meta-analysis of genome-wide association studies of adult height in East Asians ...</a><div class="ralinkpop offscreen_noflow">Meta-analysis of genome-wide association studies of adult height in East Asians identifies 17 novel loci<div class="brieflinkpopdesc">Human Molecular Genetics. 2015 Mar 15; 24(6)1791</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=4" href="/portal/utils/pageresolver.fcgi?recordid=5dd57ef139a66eb03db82cc0">Common variation in PHACTR1 is associated with susceptibility to cervical artery...</a><div class="ralinkpop offscreen_noflow">Common variation in PHACTR1 is associated with susceptibility to cervical artery dissection<div class="brieflinkpopdesc">NIHPA Author Manuscripts. 2015 Jan; 47(1)78</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=5" href="/portal/utils/pageresolver.fcgi?recordid=5dd57ec6dde0893a8bc2db2d">Meta-analysis of genome-wide association studies for circulating phylloquinone c...</a><div class="ralinkpop offscreen_noflow">Meta-analysis of genome-wide association studies for circulating phylloquinone concentrations<div class="brieflinkpopdesc">The American Journal of Clinical Nutrition. 2014 Dec; 100(6)1462</div>
</div>
<div class="tertiary"></div>
</li>
</ul>
<p class="HTOn">Your browsing activity is empty.</p>
<p class="HTOff">Activity recording is turned off.</p>
<p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p>
<a class="seemore" href="/sites/myncbi/recentactivity">See more...</a>
</div></div></div>
</div>
<div>
<div class="portlet brieflink pmc_para_cit" id="crb--P5" name="crb--P5" rid="P5" style="position: absolute; visibility: visible; width: 370px; top: 1387px; display: none;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-24"><ul>
<li class="two_line" reference_id="R2">
<a href="/pubmed/16905783/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.</a><span class="one_line_source">[JAMA.  2006]</span><div class="alt-note">
<div class="authors">Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR, AIDS Clinical Trials Group (ACTG) A5095 Study Team.</div>
<div class="citation">JAMA. 2006 Aug 16; 296(7):769-81.</div>
</div>
</li>
<li class="two_line" reference_id="R9">
<a href="/pubmed/22343174/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.</a><span class="one_line_source">[J Acquir Immune Defic Syndr.  2012]</span><div class="alt-note">
<div class="authors">Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, Wu H, Johnson MA, Saag M, Supparatpinyo K, Crauwels H, Lefebvre E, Rimsky LT, Vanveggel S, Williams P, Boven K, ECHO Study Group., THRIVE Study Group.</div>
<div class="citation">J Acquir Immune Defic Syndr. 2012 May 1; 60(1):33-42.</div>
</div>
</li>
<li class="two_line" reference_id="R10">
<a href="/pubmed/11809184/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.</a><span class="one_line_source">[Lancet.  2002]</span><div class="alt-note">
<div class="authors">Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A, Swiss HIV Cohort Study.</div>
<div class="citation">Lancet. 2002 Jan 5; 359(9300):30-6.</div>
</div>
</li>
<li class="two_line" reference_id="R11">
<a href="/pubmed/20662624/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.</a><span class="one_line_source">[J Infect Dis.  2010]</span><div class="alt-note">
<div class="authors">Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D, Haas DW</div>
<div class="citation">J Infect Dis. 2010 Sep 1; 202(5):717-22.</div>
</div>
</li>
<li class="two_line" reference_id="R12">
<a href="/pubmed/12676886/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.</a><span class="one_line_source">[J Pharmacol Exp Ther.  2003]</span><div class="alt-note">
<div class="authors">Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z</div>
<div class="citation">J Pharmacol Exp Ther. 2003 Jul; 306(1):287-300.</div>
</div>
</li>
<li class="two_line" reference_id="R13">
<a href="/pubmed/24695352/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.</a><span class="one_line_source">[J Antimicrob Chemother.  2014]</span><div class="alt-note">
<div class="authors">Haas DW, Severe P, Jean Juste MA, Pape JW, Fitzgerald DW</div>
<div class="citation">J Antimicrob Chemother. 2014 Aug; 69(8):2187-90.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P6" name="crb--P6" rid="P6" style="position: absolute; visibility: visible; width: 370px; top: 1684px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-25"><ul>
<li class="two_line" reference_id="R14">
<a href="/pubmed/15622315/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.</a><span class="one_line_source">[AIDS.  2004]</span><div class="alt-note">
<div class="authors">Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP</div>
<div class="citation">AIDS. 2004 Dec 3; 18(18):2391-400.</div>
</div>
</li>
<li class="two_line" reference_id="R19">
<a href="/pubmed/23080225/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.</a><span class="one_line_source">[Pharmacogenet Genomics.  2012]</span><div class="alt-note">
<div class="authors">Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW</div>
<div class="citation">Pharmacogenet Genomics. 2012 Dec; 22(12):858-67.</div>
</div>
</li>
<li class="two_line" reference_id="R11">
<a href="/pubmed/20662624/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.</a><span class="one_line_source">[J Infect Dis.  2010]</span><div class="alt-note">
<div class="authors">Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D, Haas DW</div>
<div class="citation">J Infect Dis. 2010 Sep 1; 202(5):717-22.</div>
</div>
</li>
<li class="two_line" reference_id="R21">
<a href="/pubmed/16495778/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz.</a><span class="one_line_source">[Pharmacogenet Genomics.  2006]</span><div class="alt-note">
<div class="authors">Wang J, Sönnerborg A, Rane A, Josephson F, Lundgren S, Ståhle L, Ingelman-Sundberg M</div>
<div class="citation">Pharmacogenet Genomics. 2006 Mar; 16(3):191-8.</div>
</div>
</li>
<li class="two_line" reference_id="R23" style="display: none;">
<a href="/pubmed/12698988/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Population pharmacokinetic meta-analysis with efavirenz.</a><span class="one_line_source">[Int J Clin Pharmacol Ther.  2002]</span><div class="alt-note">
<div class="authors">Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ Jr</div>
<div class="citation">Int J Clin Pharmacol Ther. 2002 Nov; 40(11):507-19.</div>
</div>
</li>
<li class="two_line" reference_id="R24" style="display: none;">
<a href="/pubmed/12499180/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.</a><span class="one_line_source">[Antimicrob Agents Chemother.  2003]</span><div class="alt-note">
<div class="authors">Pfister M, Labbé L, Hammer SM, Mellors J, Bennett KK, Rosenkranz S, Sheiner LB, Adult AIDS Clinical Trial Group Study 398.</div>
<div class="citation">Antimicrob Agents Chemother. 2003 Jan; 47(1):130-7.</div>
</div>
</li>
</ul><a href="" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P7" name="crb--P7" rid="P7" style="position: absolute; visibility: visible; width: 370px; top: 1915px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-26"><ul>
<li class="two_line" reference_id="R26">
<a href="/pubmed/11888582/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.</a><span class="one_line_source">[Lancet.  2002]</span><div class="alt-note">
<div class="authors">Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT</div>
<div class="citation">Lancet. 2002 Mar 2; 359(9308):727-32.</div>
</div>
</li>
<li class="two_line" reference_id="R28">
<a href="/pubmed/18256392/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">HLA-B*5701 screening for hypersensitivity to abacavir.</a><span class="one_line_source">[N Engl J Med.  2008]</span><div class="alt-note">
<div class="authors">Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A, PREDICT-1 Study Team.</div>
<div class="citation">N Engl J Med. 2008 Feb 7; 358(6):568-79.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P8" name="crb--P8" rid="P8" style="position: absolute; visibility: visible; width: 370px; top: 2102px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-27"><ul>
<li class="two_line" reference_id="R29">
<a href="/pubmed/19952143/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.</a><span class="one_line_source">[N Engl J Med.  2009]</span><div class="alt-note">
<div class="authors">Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES, AIDS Clinical Trials Group Study A5202 Team.</div>
<div class="citation">N Engl J Med. 2009 Dec 3; 361(23):2230-40.</div>
</div>
</li>
<li class="two_line" reference_id="R30">
<a href="/pubmed/19542866/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.</a><span class="one_line_source">[AIDS.  2009]</span><div class="alt-note">
<div class="authors">Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS, HEAT Study Team.</div>
<div class="citation">AIDS. 2009 Jul 31; 23(12):1547-56.</div>
</div>
</li>
<li class="two_line" reference_id="R31">
<a href="/pubmed/24195548/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.</a><span class="one_line_source">[N Engl J Med.  2013]</span><div class="alt-note">
<div class="authors">Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators.</div>
<div class="citation">N Engl J Med. 2013 Nov 7; 369(19):1807-18.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P10" name="crb--P10" rid="P10" style="position: absolute; visibility: visible; width: 370px; top: 2514px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-28"><ul>
<li class="two_line" reference_id="R32">
<a href="/pubmed/14668455/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.</a><span class="one_line_source">[N Engl J Med.  2003]</span><div class="alt-note">
<div class="authors">Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS, AIDS Clinical Trials Group 384 Team.</div>
<div class="citation">N Engl J Med. 2003 Dec 11; 349(24):2293-303.</div>
</div>
</li>
<li class="two_line" reference_id="R33">
<a href="/pubmed/14668456/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.</a><span class="one_line_source">[N Engl J Med.  2003]</span><div class="alt-note">
<div class="authors">Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC, AIDS Clinical Trials Group 384 Team.</div>
<div class="citation">N Engl J Med. 2003 Dec 11; 349(24):2304-15.</div>
</div>
</li>
<li class="two_line" reference_id="R2">
<a href="/pubmed/16905783/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.</a><span class="one_line_source">[JAMA.  2006]</span><div class="alt-note">
<div class="authors">Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR, AIDS Clinical Trials Group (ACTG) A5095 Study Team.</div>
<div class="citation">JAMA. 2006 Aug 16; 296(7):769-81.</div>
</div>
</li>
<li class="two_line" reference_id="R4">
<a href="/pubmed/18480202/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Class-sparing regimens for initial treatment of HIV-1 infection.</a><span class="one_line_source">[N Engl J Med.  2008]</span><div class="alt-note">
<div class="authors">Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW, AIDS Clinical Trials Group Study A5142 Team.</div>
<div class="citation">N Engl J Med. 2008 May 15; 358(20):2095-106.</div>
</div>
</li>
<li class="two_line" reference_id="R7">
<a href="/pubmed/21320923/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.</a><span class="one_line_source">[Ann Intern Med.  2011]</span><div class="alt-note">
<div class="authors">Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC, AIDS Clinical Trials Group Study A5202 Team.</div>
<div class="citation">Ann Intern Med. 2011 Apr 5; 154(7):445-56.</div>
</div>
</li>
<li class="two_line" reference_id="R29">
<a href="/pubmed/19952143/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.</a><span class="one_line_source">[N Engl J Med.  2009]</span><div class="alt-note">
<div class="authors">Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES, AIDS Clinical Trials Group Study A5202 Team.</div>
<div class="citation">N Engl J Med. 2009 Dec 3; 361(23):2230-40.</div>
</div>
</li>
<li class="two_line" reference_id="R34">
<a href="/pubmed/14583845/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.</a><span class="one_line_source">[HIV Clin Trials.  2003]</span><div class="alt-note">
<div class="authors">Haas DW, Wilkinson GR, Kuritzkes DR, Richman DD, Nicotera J, Mahon LF, Sutcliffe C, Siminski S, Andersen J, Coughlin K, Clayton EW, Haines J, Marshak A, Saag M, Lawrence J, Gustavson J, Anne Bennett J, Christensen R, Matula MA, Wood AJ, Adult AIDS Clinical Trials Group.</div>
<div class="citation">HIV Clin Trials. 2003 Sep-Oct; 4(5):287-300.</div>
</div>
</li>
<li class="two_line" reference_id="R11" style="display: none;">
<a href="/pubmed/20662624/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.</a><span class="one_line_source">[J Infect Dis.  2010]</span><div class="alt-note">
<div class="authors">Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D, Haas DW</div>
<div class="citation">J Infect Dis. 2010 Sep 1; 202(5):717-22.</div>
</div>
</li>
</ul><a href="" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P12" name="crb--P12" rid="P12" style="position: absolute; visibility: visible; width: 370px; top: 3211px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-29"><ul>
<li class="two_line" reference_id="R35">
<a href="/pubmed/21051598/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.</a><span class="one_line_source">[Science.  2010]</span><div class="alt-note">
<div class="authors">International HIV Controllers Study., Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G Jr, Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC Jr, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL Jr, Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, Mcleod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC 3rd, Olender SA, Ostrowski M, Owen WF Jr, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC 3rd, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM Jr, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Telenti A, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M</div>
<div class="citation">Science. 2010 Dec 10; 330(6010):1551-7.</div>
</div>
</li>
<li class="two_line" reference_id="R36">
<a href="/pubmed/17701901/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PLINK: a tool set for whole-genome association and population-based linkage analyses.</a><span class="one_line_source">[Am J Hum Genet.  2007]</span><div class="alt-note">
<div class="authors">Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC</div>
<div class="citation">Am J Hum Genet. 2007 Sep; 81(3):559-75.</div>
</div>
</li>
<li class="two_line" reference_id="R37">
<a href="/pubmed/16862161/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Principal components analysis corrects for stratification in genome-wide association studies.</a><span class="one_line_source">[Nat Genet.  2006]</span><div class="alt-note">
<div class="authors">Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D</div>
<div class="citation">Nat Genet. 2006 Aug; 38(8):904-9.</div>
</div>
</li>
<li class="two_line" reference_id="R38">
<a href="/pubmed/19200528/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals.</a><span class="one_line_source">[Am J Hum Genet.  2009]</span><div class="alt-note">
<div class="authors">Browning BL, Browning SR</div>
<div class="citation">Am J Hum Genet. 2009 Feb; 84(2):210-23.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P16" name="crb--P16" rid="P16" style="position: absolute; visibility: visible; width: 370px; top: 5844px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-30"><ul><li class="two_line" reference_id="R40">
<a href="/pubmed/20714348/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits.</a><span class="one_line_source">[PLoS Genet.  2010]</span><div class="alt-note">
<div class="authors">Segrè AV, DIAGRAM Consortium., MAGIC investigators., Groop L, Mootha VK, Daly MJ, Altshuler D</div>
<div class="citation">PLoS Genet. 2010 Aug 12; 6(8):.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P22" name="crb--P22" rid="P22" style="position: absolute; visibility: visible; width: 370px; top: 7655px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-31"><ul><li class="two_line" reference_id="R19">
<a href="/pubmed/23080225/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.</a><span class="one_line_source">[Pharmacogenet Genomics.  2012]</span><div class="alt-note">
<div class="authors">Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW</div>
<div class="citation">Pharmacogenet Genomics. 2012 Dec; 22(12):858-67.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P24" name="crb--P24" rid="P24" style="position: absolute; visibility: visible; width: 370px; top: 8888px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-32"><ul>
<li class="two_line" reference_id="R2">
<a href="/pubmed/16905783/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.</a><span class="one_line_source">[JAMA.  2006]</span><div class="alt-note">
<div class="authors">Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR, AIDS Clinical Trials Group (ACTG) A5095 Study Team.</div>
<div class="citation">JAMA. 2006 Aug 16; 296(7):769-81.</div>
</div>
</li>
<li class="two_line" reference_id="R9">
<a href="/pubmed/22343174/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.</a><span class="one_line_source">[J Acquir Immune Defic Syndr.  2012]</span><div class="alt-note">
<div class="authors">Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, Wu H, Johnson MA, Saag M, Supparatpinyo K, Crauwels H, Lefebvre E, Rimsky LT, Vanveggel S, Williams P, Boven K, ECHO Study Group., THRIVE Study Group.</div>
<div class="citation">J Acquir Immune Defic Syndr. 2012 May 1; 60(1):33-42.</div>
</div>
</li>
<li class="two_line" reference_id="R29">
<a href="/pubmed/19952143/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.</a><span class="one_line_source">[N Engl J Med.  2009]</span><div class="alt-note">
<div class="authors">Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES, AIDS Clinical Trials Group Study A5202 Team.</div>
<div class="citation">N Engl J Med. 2009 Dec 3; 361(23):2230-40.</div>
</div>
</li>
<li class="two_line" reference_id="R31">
<a href="/pubmed/24195548/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.</a><span class="one_line_source">[N Engl J Med.  2013]</span><div class="alt-note">
<div class="authors">Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators.</div>
<div class="citation">N Engl J Med. 2013 Nov 7; 369(19):1807-18.</div>
</div>
</li>
<li class="two_line" reference_id="R41" style="display: none;">
<a href="/pubmed/15247553/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.</a><span class="one_line_source">[J Acquir Immune Defic Syndr.  2004]</span><div class="alt-note">
<div class="authors">Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M</div>
<div class="citation">J Acquir Immune Defic Syndr. 2004 Aug 15; 36(5):1011-9.</div>
</div>
</li>
<li class="two_line" reference_id="R42" style="display: none;">
<a href="/pubmed/15094269/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.</a><span class="one_line_source">[Lancet.  2004]</span><div class="alt-note">
<div class="authors">van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM, 2NN Study team.</div>
<div class="citation">Lancet. 2004 Apr 17; 363(9417):1253-63.</div>
</div>
</li>
<li class="two_line" reference_id="R19" style="display: none;">
<a href="/pubmed/23080225/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.</a><span class="one_line_source">[Pharmacogenet Genomics.  2012]</span><div class="alt-note">
<div class="authors">Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW</div>
<div class="citation">Pharmacogenet Genomics. 2012 Dec; 22(12):858-67.</div>
</div>
</li>
</ul><a href="" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P26" name="crb--P26" rid="P26">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-33"><ul>
<li class="expanded" reference_id="R43">
<a href="/pubmed/18301416/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.</a><span class="one_line_source">[Pharmacogenomics J.  2009]</span><div class="alt-note">
<div class="authors">Nelson MR, Bacanu SA, Mosteller M, Li L, Bowman CE, Roses AD, Lai EH, Ehm MG</div>
<div class="citation">Pharmacogenomics J. 2009 Feb; 9(1):23-33.</div>
</div>
</li>
<li class="expanded" reference_id="R44">
<a href="/pubmed/21659334/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.</a><span class="one_line_source">[Hum Mol Genet.  2011]</span><div class="alt-note">
<div class="authors">Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, Enomoto N, Yatsuhashi H, Nishiguchi S, Hino K, Hige S, Itoh Y, Tanaka E, Mochida S, Honda M, Hiasa Y, Koike A, Sugauchi F, Kaneko S, Izumi N, Tokunaga K, Mizokami M</div>
<div class="citation">Hum Mol Genet. 2011 Sep 1; 20(17):3507-16.</div>
</div>
</li>
<li class="expanded" reference_id="R45">
<a href="/pubmed/18650507/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">SLCO1B1 variants and statin-induced myopathy--a genomewide study.</a><span class="one_line_source">[N Engl J Med.  2008]</span><div class="alt-note">
<div class="authors">SEARCH Collaborative Group., Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R</div>
<div class="citation">N Engl J Med. 2008 Aug 21; 359(8):789-99.</div>
</div>
</li>
<li class="expanded" reference_id="R46">
<a href="/pubmed/21810746/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash.</a><span class="one_line_source">[Clin Infect Dis.  2011]</span><div class="alt-note">
<div class="authors">Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, Tantisiriwat W, Charoenyingwattana A, Sura T, Takahashi A, Kubo M, Kamatani N, Chantratita W, Nakamura Y</div>
<div class="citation">Clin Infect Dis. 2011 Aug; 53(4):341-8.</div>
</div>
</li>
<li class="expanded" reference_id="R47">
<a href="/pubmed/18294295/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.</a><span class="one_line_source">[Cancer Sci.  2008]</span><div class="alt-note">
<div class="authors">Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y</div>
<div class="citation">Cancer Sci. 2008 May; 99(5):967-72.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P27" name="crb--P27" rid="P27">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-34"><ul>
<li class="expanded" reference_id="R48">
<a href="/pubmed/15627041/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts.</a><span class="one_line_source">[AIDS.  2005]</span><div class="alt-note">
<div class="authors">Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, Phillips E, Christiansen FT, Mallal S</div>
<div class="citation">AIDS. 2005 Jan 3; 19(1):97-9.</div>
</div>
</li>
<li class="expanded" reference_id="R49">
<a href="/pubmed/21150552/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.</a><span class="one_line_source">[AIDS.  2011]</span><div class="alt-note">
<div class="authors">Kwara A, Lartey M, Sagoe KW, Court MH</div>
<div class="citation">AIDS. 2011 Jan 28; 25(3):388-90.</div>
</div>
</li>
<li class="expanded" reference_id="R50">
<a href="/pubmed/24557078/" ref="reftype=pubmed&amp;article-id=4387236&amp;issue-id=251462&amp;journal-id=319&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.</a><span class="one_line_source">[Pharmacogenet Genomics.  2014]</span><div class="alt-note">
<div class="authors">Johnson DH, Venuto C, Ritchie MD, Morse GD, Daar ES, McLaren PJ, Haas DW</div>
<div class="citation">Pharmacogenet Genomics. 2014 Apr; 24(4):195-203.</div>
</div>
</li>
</ul></div>
</div>
</div>   
    </div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-11-20T13:01:39-05:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=portal105&amp;ncbi_phid=CE8C28A4DD573F2100000000079E049F&amp;ncbi_session=CE8C6010DD4F8B31_0740SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4387236%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 68.1px; left: 377.2px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: block;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: block;">Turn off</a></div></div><div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=nihpa&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC4387236/&amp;ncbi_app=pmc" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C6010DD4F8B31_0740SID /projects/PMC/PMCViewer@4.46 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" style="display: none;" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div></body></html>